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It is universally acknowledged that older people differ greatly from each other. For 
example, there is the healthy (sometimes wealthy) person, aged 75 years and over, who 
plays tennis or golf, still volunteers for activities with a social interest, frequently goes on 
holiday, and is still working on lifestyle improvements. On the other hand, there is the 
fragile widowed patient with decreased cognitive function, with only moderate self-care 
and health illiteracy. Is it justified to categorise these two types of older individuals into 
the same group for preventive strategies, even though their life expectancy, and levels 
of wellbeing and functioning are very different? 
In current national prevention programs no difference is made between these types of 
individuals. For example, for breast cancer screening the woman’s age is the stratifying 
criterion (i.e. 50-75 years). In a civil court case challenging the age criteria laid down in 
the permit for performing preventive breast cancer screening, the applicants argued 
that selection on the basis of age constituted a forbidden form of age discrimination by 
excluding women older than 75 years. The court of appeal concluded, however, that the 
medical reasons underlying this form of different treatment objectively justified using 
age as a selection criterion. The court concurred with the State that issued the permit, 
that for some women aged over 75 years preventive breast cancer screening might be 
beneficial, but that a collective approach for women older than 75 years would not be 
effective.1 Therefore, when more health-specific criteria have been developed, it is pos-
sible that age will no longer be the most suitable selection criteria. This reasoning might 
also be applicable to other types of preventive care for older people. The work in this 
thesis investigates the possibilities to develop subgroup-specific preventive strategies 
for older people.
Demography of older people
Worldwide, the proportion of aged persons is growing faster than any other age group.2 
It is estimated that in the Netherlands by 2040, 26% of the population will be aged 65 
years and older; of these, about one third will be aged over 80 years. Moreover, by 2060 
it is expected that the proportion aged over 65 years will increase to 39%.3
The relative growth of the aged population is partly due to the ‘baby boom’ after World 
War II and to the increasing life expectancy. In the period 1950-2010 in the Netherlands, 
the life expectancy of men increased from 70.4 to 78.8 years and for women from 72.7 to 
82.7 years.4 However, the growing life expectancy does not necessarily imply an increas-
ing number of years without chronic disease. On the contrary, life expectancy without 
chronic diseases has decreased in the Netherlands:5 e.g. diseases like coronary heart 
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disease, depression, anxiety disorders, diabetes, stroke and arthritis are responsible for 
the greatest number of years lived with disability.6 
In the context of these demographic developments healthy aging is a prominent theme 
in current international health policy.7-10 The goal of healthy aging is not only a matter 
of maintaining good physical and mental health, but also of older people remaining 
independent and participating in social activities. It is of considerable importance 
for the coming years to develop strategies in health care for older people, which not 
only contribute to life expectancy but also to functioning in daily life and wellbeing. 
Nowadays, the number of people available to work is about four times the population 
of older persons. Due to changes in demography in the future, this ratio will change: it 
is estimated that in 2039 the number of people available to work will be only about two 
times the size of the older population.11 Therefore, a shortage of personnel in health care 
can be foreseen. This shortage might be compensated by increasing the independence 
level of older people, thereby reducing the need for professionals in health and home 
care.
Preventive strategies in older people 
Aims
Preventive care traditionally refers to measures taken to prevent disease, injury and 
death. In older persons, however, no breakthroughs in the prevention and treatment of 
diseases are expected in the short term. Therefore, according to the Health Council of 
the Netherlands, prevention in older people might also be used to contribute to the goal 
of healthy aging, i.e. the maintenance of independence and wellbeing by preventing or 
postponing disability and social isolation. This functional approach seems to be more 
promising and may also limit the need for care.12 However, research on the effectiveness 
of preventive strategies to contribute to independence is lacking.
Strategies
Preventive strategies can be classified into four types of approach: universal, selective, 
indicated, and care-related prevention. Universal and selective prevention are based on 
a collective approach, whereas indicated and care-related prevention need an individu-
alized approach (Figure 1).13-15
Universal prevention is desirable for the population (or subgroups) in general and should 
be applied to persons not motivated by current complaints or symptoms. This category 
comprises all those measures which can be advocated for the general public, aiming 
at health improvement and a decrease in risk of disease. Selective prevention is recom-
mended for specific groups in the population with increased risk, and aims at improve-
10
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ment of health of these specific risk groups. The third class of preventive measures, 
called indicated prevention, encompasses individuals who do not yet have a diagnosed 
disease but who do have complaints or mild symptoms. The aim of indicated prevention 
is to prevent the onset of disease or health damage. The fourth category of preventive 
care is care-related prevention, which aims at individuals with an established disease to 
reduce the burden of disease and to prevent complications, comorbidity and disability. 
According to this classification, preventive programs can be organized collectively or 
individually. However, it is still unclear which approach is appropriate in preventive 
care for older people. Since 2008, the Dutch Public Health Act (Wet publieke gezondheid: 
WPG) stipulates that the local authorities (more precisely city councils) are responsible 
for the provision of health care to the elderly, including systematic monitoring of the 
health status of older people and the early detection and prevention of specific disor-
ders like comorbidity.16 According to the Act’s explanation memorandum, the central 
government aims at prevention of comorbidity and prevention of health problems like 
decubitus, undernutrition, dehydration and intertrigo.17 This section of the Act is placed 
directly after the provisions on youth health care and suggests that elderly health care 



















































Figure 1. Classification of preventive strategies.15
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However, it has been shown that a collective approach by screening community-
dwelling older people for specific highly-prevalent disorders (such as hearing loss and 
impaired vision) is not effective.18-23 Furthermore, screening older people for depressive 
symptoms by the general practitioner (GP) in order to offer them an intervention, was 
also not effective.24 These screening programs did not fulfil the criteria for screening 
formulated in 1968 by Wilson and Jungner, in particular the criterion which demands 
that there should be an accepted treatment for patients with recognized disease and 
the criterion that the costs should be economically balanced in relation to possible 
expenditure on medical care as a whole.25 
A possible explanation for the finding in these studies that a collective screening ap-
proach is not effective, is that in older persons health is a product of lifetime influences 
of diseases, lifestyle, environment and personal preferences in self-determination, ac-
cumulating in a variety of health status, functional status and expectations in older 
persons. Therefore, the perspectives on aged-related medical problems will differ con-
siderably between older people. For example, is hearing impairment in older people a 
medical disorder or a normal, age-related decrease in functioning? A targeted approach 
to specific subgroups will probably be beneficial to prevent specific diseases or disor-
ders, while a collective approach to the general older population is not effective.
Integration of subgroup-specific aims and strategies
Thus, for the development of effective preventive care for older people it is neces-
sary to consider both the aim and the strategy. First, which aim of prevention should 
be pursued for older people: prevention of diseases and injury to contribute to life 
expectancy, or the maintenance of independence in daily life and wellbeing? Second, 
which strategy might be appropriate: a collective strategy targeting at (subgroups of ) 
community-dwelling older people, or an individualized approach, targeting persons 
with complaints, symptoms or diseases for whom the preventive strategy can be cus-
tomized to personal circumstances?
Figure 2 depicts these two dimensions of preventive care for older persons. This figure 
divides the preventive strategies into four quadrants, depending on the aim of preven-
tion and the approach. In relation to this figure, the main question is: which preventive 
interventions for which subgroup of older persons might be applicable in each quadrant. 
To select these subgroups for interventions it is necessary to find predictors to stratify. 
12
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Current practice in the Netherlands
Activities to prevent disease
In current practice, the most prominent preventive activities for older people take place 
in order to prevent disease and therefore belong to the upper half of the circle. Below, 
two examples are described: the national programs for screening and for prevention, 
and cardiovascular risk management.
National programs for screening and vaccination
Breast cancer screening, colon cancer screening and influenza vaccination are collective 
preventive care strategies aiming to prevent disease, and fit in the left upper quadrant. 
These programs target subgroups of community-dwelling older people, defined by sex, 
age and specific indications, such as diabetes mellitus. 
Cardiovascular risk management
Cardiovascular risk management, another prominent preventive activity in the Nether-
lands, also fits in the upper half of the circle. The aim of cardiovascular risk management 
is to reduce the incidence of cardiovascular events in a high-risk population. For preven-
tion of cardiovascular disease both the collective and the individual approach is used. 
Prevention of cardiovascular disease in persons with a history of cardiovascular disease 
obviously follows an individual approach, because prevention of recurrent disease 
belongs to the care-related individual approach.
 
Maintenance of independence and well-being 
Collective approach  Individual  approach 
Prevention of disease or injury 
Figure 2. Aims and approaches in preventive strategies.
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Providing lifestyle information to the general public by public health agencies and other 
organizations follows a collective approach. Another collective activity is the recently 
introduced ‘prevention consultation’ by GPs, which uses an open internet-based invita-
tion to the general public to screen for risk factors for cardiovascular disease.26 However, 
this consultation explicitly excludes older people because of their predetermined age-
related higher risk. 
Apart from these collective strategies, cardiovascular risk management for people 
without cardiovascular disease is mainly based on case finding carried out by GPs. Case 
finding comprises both selective prevention and indicated prevention. To identify indi-
viduals with a high cardiovascular risk, GPs often use clinical cardiovascular risk scores, 
such as the Framingham Risk Score27 and the Systematic Coronary Risk Evaluation 
(SCORE).28 However, their accuracy to predict risk on cardiovascular outcomes is clearly 
reduced in older persons.29-32 Recently, the Leiden 85-plus Study and others have shown 
that homocysteine is predictive for cardiovascular events in old age.33-38 However, it is 
not clear whether preventive cardiovascular treatment is more effective in a group of 
older people with high risk compared to older people with low risk. 
Activities to maintain independence and wellbeing
In current practice, the market for general health checks is growing in the Netherlands. 
Especially so-called preventive health centers for seniors, to which older people are 
invited for a preventive check up, is an upcoming phenomenon. According to the 
policy document on this type of center, the aim of these centers is to improve social 
participation and social wellbeing, to enhance self-determination and to improve health 
literacy.39 These centers use a collective approach, aiming at older people without using 
various selection criteria as are used for care-related or indicated prevention. Therefore, 
preventive health checks can be placed in the lower left quadrant. According to the 
preventive health center guidebook,40 these centers try to reach this aim by screening 
older people for various conditions. However, evidence for the benefit of this type of 
screening is still lacking.18-24 
Apart from these preventive health centers, a systematic approach to realize mainte-
nance of independence and wellbeing (the lower half of the figure), is scarce. This does 
not mean that GPs and other caregivers do not work on the maintenance of indepen-
dence and wellbeing in individual cases. However, apart from care-related prevention 
in the management of specific diseases, guidelines for maintenance of independence 
and wellbeing are lacking. To identify patients for whom preventive strategies aiming at 
maintenance of independence would be beneficial, instruments are needed to identify 
older people at high risk to develop disability in the near future. It is known that chronic 
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diseases41-47 and multimorbidity46-48 are strongly related with disability, but the predic-
tive value of these factors for disability differs according to the health status of the older 
individual. When such instruments become available, older people can pro-actively be 
approached (collectively or individually) to prevent increase in disability, thereby result-
ing in the maintenance of independence and wellbeing. 
Conclusion
In conclusion, in current practice, the most prominent preventive activities for older per-
sons are related to the prevention of disease. However, there is room for improvement in 
the current cardiovascular risk management strategy, which is widely used for the pre-
vention of cardiovascular disease in older persons. Moreover, it is still unknown which 
preventive activities can contribute to maintaining an acceptable level of functioning in 
daily life and wellbeing. In addition, instruments to identify eligible risk groups for this 
approach are lacking.
Therefore, it is important to explore the ideas of caregivers about the possibility to 
develop strategies in preventive care for older people to prevent disease or to maintain 
independence. To develop aim-specific collective preventive care for older persons, not 
only are instruments needed to define and select subgroups of older people at risk for 
disease or at risk for loss of independence, but also adequate interventions need to be 
available to prevent disease or to maintain independence.
Aim of this thesis 
The general aim of the work in this thesis is to study the strategies in preventive care 
(varying in their aim and approach) for older people to facilitate the development of 
subgroup-specific evidence-based guidelines for preventive care for older persons. 
To achieve this aim, the following questions were explored:
1. Is there scientific support for the idea that the aim of prevention is not only to pre-
vent disease and injury, but also to maintain independence and wellbeing?
2. In order to aim at maintenance of independence and wellbeing: 
a. Is it possible to identify older people who will benefit from a preventive approach 
which contributes to the maintenance of independence and wellbeing?
b. Which preventive strategies are appropriate to contribute to the maintenance of 
independence and wellbeing?
3. In order to aim at prevention of disease, with a focus on cardiovascular disease: 
a. Is it possible to identify subgroups by screening older people to prevent disease?
b. Is a high-risk approach an appropriate preventive strategy to contribute to preven-
tion of cardiovascular disease in older persons?
Introduction
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Brief description of chapters
1. Exploration of aims in preventive care for older people
Chapter 2 describes the perspectives of general practitioners (GPs) on preventive care 
for older people: these were examined in six focus groups. Perceptions of GPs regarding 
preventive care for older people, and the individual motivations of GPs for variation 
in preventive care, are largely unknown. Moreover, it is unclear whether GPs deliver 
preventive care in the traditional way, i.e. mainly to prevent diseases or injuries, or to 
maintain independence and wellbeing. Therefore, this qualitative study explores GPs’ 
perspectives on preventive care to elucidate their ideas about the aim, organisation and 
content of preventive care for older people. This investigation will reveal the direction 
in which preventive care for older people, according to GPs, needs to be developed in 
the future. 
2. Maintenance of independence and wellbeing 
a. Specifying subgroups of older people
The aim of prevention probably depends on the health status of older persons, because 
values such as functioning in daily life and wellbeing become more important than life 
expectancy when the general health of older individuals declines.12 To develop aim-
specific evidence-based guidelines for preventive care for older people, instruments 
are needed to define and select subgroups. Chapter 3 describes the predictive value of 
multimorbidity for the development of disability in the general population of very old 
people and the role of cognitive impairment in this association. Chapter 4 investigates 
the variation in vulnerability concepts between the GPs and determines whether GPs 
have common or distinctive concepts of vulnerability in mind. If the variability between 
GPs proves to be small, assessment by GPs could be an effective instrument to select 
older people for geriatric care.
b. Preventive strategies to maintain independence and wellbeing
After exploring the possibilities to define subgroups, we investigated which conditions 
are appropriate for a collective approach to maintain independence and wellbeing. In 
Chapter 5 a RAND/UCLA appropriateness method was carried out to identify appropri-
ate screening conditions to prevent functional decline in older people, stratified for age 
and vulnerability.
3. Prevention of disease with a focus on cardiovascular disease
a. Specifying subgroups of older people 
In current guidelines for cardiovascular risk management, which primarily aim at pre-
venting disease, the cardiovascular risk determinants (as selection criteria for preventive 
cardiovascular treatment) are insufficient for older persons. To select subgroups of older 
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people who are expected to derive the most benefit from preventive cardiovascular 
treatment, appropriate risk stratification instruments are needed. Furthermore, the 
influence of cardiovascular disease on the maintenance of independence and wellbe-
ing needs to be investigated, because prevention of non-fatal cardiovascular disease 
probably not only improves life expectancy but also functional status and wellbeing. 
Chapter 6 investigates whether there are differences in prognosis between very old 
people with various levels of prevalent cardiovascular disease, compared to those with 
no manifest cardiovascular disease. The prognosis was studied not only with regard to 
incident cardiovascular morbidity and mortality, but also with respect to functional 
status. If risk stratification proves predictive not only for morbidity and mortality but 
also for functional status, then cardiovascular risk stratification will contribute to both 
aims, i.e. the prevention of disease and the maintenance of a person’s independence.
b. Preventive strategies in cardiovascular risk management
Chapter 7 describes the effect of preventive pravastatin treatment in older people strati-
fied into three groups at risk for cardiovascular disease based on their plasma levels of 
homocysteine. Since, according to Wilson and Jungner, risk predictors are clinically 
meaningful only when effective preventive treatment is available,25 we need to establish 
which treatment possibilities are appropriate for older persons with high homocysteine 
to lower their cardiovascular risk. Therefore, a post-hoc subanalysis was performed in 
PROSPER49 (a large double-blinded randomized placebo-controlled trial) to assess the 
effect of pravastatin on the risk for coronary heart disease and mortality in older per-
sons, stratified for plasma levels of homocysteine.
General discussion and summary
Chapter 8 presents a general discussion on the main findings of the work in this thesis, 
considers the clinical implications of the results, and makes some recommendations for 
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Preventive care traditionally aims to prevent diseases or injuries. For older people, dif-
ferent aims of prevention, such as maintenance of independence and wellbeing, are 
increasingly important.
Aim
To explore GPs’ perspectives on preventive care for older people.
Design and setting
Qualitative study comprising six focus groups with GPs in the Netherlands.
Method 
The focus-group discussions with 37 GPs were analysed using the framework analysis 
method.
Results
Whether or not to implement preventive care for older people depends on the patient’s 
individual level of vitality, as perceived by the GP. For older people with a high level of 
vitality, GPs confine their role to standardised disease-oriented prevention on a patient’s 
request; when the vitality levels in older people fall, the scope of preventive care shifts 
from prevention of disease to prevention of functional decline. For older, vulnerable 
people, GPs expect most benefit from a proactive, individualised approach, enabling 
them to live as independently as possible. Based on these perspectives, a conceptual 
model for preventive care was developed, which describes GPs’ different perspectives 
toward older people who are vulnerable and those with high levels of vitality. It focuses 
on five main dimensions: aim of care (prevention of disease versus prevention of func-
tional decline), concept of care (disease model versus functional model), initiator (older 
persons themselves versus GP), target groups (people with requests versus specified risk 
groups), and content of preventive care (mainly cardiovascular risk management versus 
functional decline).
Conclusion
GPs’ perspectives on preventive care are determined by their perception of the level of 
vitality of their older patients. Preventive care for older people with high levels of vitality 
may consist of a standardised disease-oriented approach; those who are vulnerable will 
need an individualised approach to prevent functional decline.
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HOW THIS FITS IN
Preventive care usually refers to measures that are taken to prevent diseases and injuries. 
In this study, GPs described the need for a paradigm shift in preventive care for older 
people. In persons with high levels of vitality, they found it important to focus on pre-
venting or postponing diseases as in younger age groups, preferably with standardised 
programmes. However, in vulnerable older people this study found that preventive care 
needs a more individualised approach that takes the preferences of the older person 




Preventive care traditionally refers to measures taken to prevent disease or injury 
and not to goals that are less well defined, such as maintenance of independence or 
wellbeing. However, for older people whose general health status is declining, values 
such as maintenance of independence in daily life and wellbeing become increasingly 
important.1 
The possibility of preventive care contributing to independence and functioning in the 
daily life of older people is relatively new in current health policy.2–4 Research on routine 
comprehensive screening for unmet health needs in the older population has revealed 
little or no benefits to the quality of life or health outcomes from such population 
screening;5 despite this, the belief that screening could prevent functional impairment 
in older people has an enduring appeal to researchers, clinicians, and older people.6,7 
In The Netherlands, preventive care for older people is generally delivered by the GP. 
Aside from national prevention programmes (for example, breast-cancer screening), 
preventive care is part of the regular primary care that is outlined in the Dutch College 
of General Practitioners’ practice guidelines.8 These guidelines are disease oriented and 
contain measures to prevent or cure diseases; they are not specifically aimed at less well-
defined goals such as the maintenance of independence or wellbeing. GPs are allowed 
to deviate from the guidelines, depending on the needs of the individual patient. In The 
Netherlands, care delivered by GPs is accessible for everyone: it is part of the obliga-
tory basic healthcare insurance and national prevention programmes are collectively 
financed.
Dutch GPs differ with regard to the type and intensity of preventive care delivered to 
their individual patients.9,10 However, GPs’ perceptions regarding preventive care for 
older people, and their individual underlying motivations for these variations, are largely 
unknown. Moreover, it is unclear whether GPs deliver preventive care in the traditional 
way — mainly to prevent diseases and injuries — or to maintain independence and 
wellbeing. This qualitative study explores GPs’ perspectives on preventive care to eluci-
date their ideas about the aim, organisation, and content of such care for older people. 
The exploration of this facet of care delivery will show the direction in which preventive 
care for older people, according to GPs, needs to be developed in the future.
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METHOD
In 2007, six focus-group discussions with GPs were conducted. To elicit GPs’ own perspec-
tives on preventive care for older people, this qualitative method was chosen to allow 
participants to articulate and discuss their own reasoning and strategies. Focus-group 
discussions were carried out instead of individual interviews as this method allows for 
interaction between the participating GPs; in-depth, emerging, complex concepts (for 
example, vitality) were explored and there was an opportunity for individuals to be 
probed for additional information.
Participants 
Participants for the focus-group discussions were invited to attend via several channels. 
A general mailing list of GPs from the northern part of the South Holland province was 
used, with individuals being invited to attend by a letter that contained four dates. The 
GPs were divided into four groups (between four and eight GPs per group) according 
to their preferred date for the discussion. Besides this, to ensure the inclusion of GPs 
specialised in the care of older people and GPs with scientific expertise, a purposive 
sampling was undertaken: GPs with special interest from the postgraduate specialisa-
tion in elderly care who had already worked as a GP for many years were recruited 
(n=7). Moreover, to ensure inclusion of GPs with scientific expertise, GPs (n=6) from the 
Department of Public Health and Primary Care of Leiden University Medical Center were 
purposively sampled. To ensure that these specialist GPs would not dominate the dis-
cussions, they were separated from the other GPs and formed two extra focus groups.11 
Interview guide and data collection 
An interview guide to explore GPs’ ideas about preventive care for older people was 
developed. The first questions asked participants to think broadly about their care for 
older people in general, their perceptions of aging, and the influence of geriatric care on 
primary care. Thereafter, the guide focused on the appropriateness of preventive health 
checks, as well as the aim, organisation, and content of preventive care for older people.
This interview guide was piloted in the first discussion group, after which only minor 
adjustments were made. As the guide remained largely the same, the data from the pilot 
group were included in the final analyses.12 
Prior to the discussion, participants gave written consent and completed a brief ques-
tionnaire about their general practice and experience; they were assured that all com-
ments would remain confidential. Each focus group was led by a researcher who was 
experienced in moderating such groups and assisted by another team member. Each 
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session lasted approximately 90 minutes (range 80–130 minutes). The researchers made 
field notes and debriefed after each session. Audiotapes were transcribed and promptly 
reviewed in order to clarify any unclear comments and/or to link each comment to the 
relevant participant.
Coding and analysis 
Following the framework analysis method,13,14 each transcript was read multiple times. 
Using thematic content analysis with an open coding system, themes emerged and were 
placed in an analytical framework for axial coding; this was discussed by the researchers 
until consensus was reached. Two researchers coded the data independently to increase 
reliability. New codes were added when considered necessary. Atlas.ti 5.2 was used 
for the analysis. After coding, the data were sorted according to the themes. The final 
stage of the analysis examined the relationships between the codes; this resulted in a 
conceptual model of GPs’ perspectives of preventive care for older people.
RESULTS
Thirty-seven GPs — 22 males and 15 females — participated in the focus-group discus-
sions. Of these, 27 (73%) had worked in general practice for ≥10 years. Twelve GPs (32%) 
reported working in practices with an over-representation of patients aged ≥65 years.
The major theme in the focus-group discussions was that GPs’ approaches to preven-
tive care for older people depended on the level of vitality of the individual person, as 
perceived by the GP. 
Five subthemes were identified: 
· aim of care; 
· concept of care; 
· initiator; 
· target groups; and 
· content of care. 
The findings form the basis of this study’s conceptual model for preventive care for 
older people (Figure 1), which comprises these five subthemes as dimensions. This 
model describes a shift in the perspective of GPs regarding older populations who have 
high levels of vitality or are vulnerable; when older people become more vulnerable, 
the scope of preventive care shifts within the five dimensions. Substantive differences 
in perspectives between the three types of GPs in the focus groups were not found, 
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although, as expected, the GPs with special interest were more used to discussing and 
reflecting on their perspectives about preventive care for older people.
Level of vitality 
During the discussions, the focus of preventive care for older patients appeared to 
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Figure 1. Conceptual model of preventative care for older people based on the present study, showing a 
shift in the perspective of GPs towards the vital and the vulnerable older populations.
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by the GP. GPs were primarily concerned about patients who they considered to be 
vulnerable and discussions mainly focused on the prevention of functional decline in 
this group. GPs differentiated between older people who are vulnerable and those with 
high vitality levels; biological age appeared to be more important than chronological 
age. Furthermore, GPs reported that their perception of old age also depended on their 
own age — the older they became, the higher were the age levels they used to classify 
someone as ‘old’. In all discussions, the perceived level of vitality tended to influence the 
GP’s policy: 
‘I don’t like to focus on age limits. I’ve heard of the term “frailty” and think it’s a good word 
to express vulnerability; I try to find out how vulnerable someone is and work within those 
limits.’ 
(Female, focus group 3, general GP).
Although definitions of older people with high levels of vitality and those who were 
vulnerable were not specifically discussed, there was no confusion among the groups 
about these two ‘types’ of older people, especially when they talked about the extremes 
as examples. All GPs appeared to have an internalised concept of ‘vitality’ and ‘vulner-
ability’.
Aim of prevention 
In the population with high levels of vitality, GPs aimed at preventing or postponing 
disease, especially cardiovascular disease. For those who were more vulnerable, they 
attempted to contribute to the patient’s quality of life by preventing or postponing 
functional decline, thereby enabling these patients to remain living independently at 
home for as long as possible: 
‘… when I start talking about prevention, the first thing that crosses my mind is the preven-
tion of breast cancer, of cervical cancer, or the prevention of … something specific. At this 
stage of their life this type of thinking is useless … What I’d like to see regarding prevention 
for the elderly is to maintain their standard of living, and all the things that are important to 
them, for as long as possible.’ 
(Male, focus group 2, general GP).
Concept of preventive care 
To achieve the various goals of prevention, GPs described the need for a paradigm shift 
in practice. In persons with high levels of vitality, they found it important to focus on pre-
venting or postponing diseases (as in younger age groups), preferably with standardised 
programmes, such as those available for breast-cancer screening for persons aged ≤75 
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years and cardiovascular health checks. In older people who are vulnerable, however, 
they found that preventive care needed a more individualised approach that took the 
preferences of the older person into account and facilitated their most important needs: 
‘I should be helping people cope better with their simple daily tasks, like being able to write 
and cut up their own food — it’s a different way of thinking. It’s looking at their situation 
from another angle. At this stage I have to forget the idea that I’m the “curing doctor” who 
only acts in response to their complaints …’ 
(Male, focus group 3, general GP).
This change in attitude and focus of care for older people who are vulnerable was clearly 
described by a GP who specialised in geriatric care: 
‘In the last few years, an important learning point for me has been to get away from the 
“disease” model and move over to the “functional” model.’ 
(Female, focus group 6, GP with special interest).
Initiator for prevention 
In general, GPs tended to hesitate about giving preventive advice to older people. They 
doubted the usefulness of such advice, as the person had already reached a respectable 
age without it: 
‘The older you are, the more you have proven your point’. 
(Female, focus group 5, general GP).
This was particularly considered to be the case for those with a good quality of life; GPs 
preferred to play ‘a waiting game’ because they were afraid of ‘patronising’ their patients: 
‘I’d always like to have some excuse to get a process going. I do agree with prevention … but 
there’ll always be that association with the idea of “patronising” people and worrying about 
medicalisation.’
(Female, focus group 1, GP with special interest). 
One GP, whose patients participated in a study on the prevalence and incidence of risk 
factors for chronic diseases in older people, noted that some individuals could be moti-
vated to change their lifestyle when, for example, abnormal laboratory tests were found. 
Usually, however, GPs assumed that people without a perceived need for help were not 
sufficiently motivated to adhere to preventive advice, especially that relating to lifestyle.
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Some GPs described a more proactive role in their preventive care for the older people 
they considered to be more vulnerable. GPs wanted to become acquainted with this 
population and to try to anticipate crises. They were also aware that some older people 
had lost their autonomy and had become increasingly dependent on them; some felt a 
considerable amount of responsibility for this kind of patient: 
‘Once people are over the age of 90, you get the idea that you’re probably the most important 
person in their life.’
(Male, focus group 1, GP with special interest).
GPs behaved proactively by making home visits, and by developing a proactive attitude 
in their consultations: 
‘I mainly think of the extra task that one gets as “care manager” … that you’re the initiator of 
a “care process” in which you try to do as little as possible, but you have to initiate it to make 
sure that the elderly are able to live their lives as comfortably as possible.’ 
(Male, focus group 1, GP with special interest).
Whereas some GPs did not make home visits (doubting its usefulness), most saw the 
benefit of these; such visits were seen as a way to monitor the home situation, such as 
checking the refrigerator or controlling medication use: 
‘I think it’s a good thing that, once in a while, you visit people who live on their own … it’s 
partly just to keep an eye on them.’
(Male, focus group 1, GP with special interest). 
Target groups 
For older people with high levels of vitality, GPs mainly targeted those who actively 
asked for preventive care. Apart from the national prevention programmes (for example, 
breast cancer screening and the influenza vaccination) and regular cardiovascular risk 
management, GPs tended to limit prevention for this population to ‘prevention on 
request’. Some GPs said they were most worried about older people who did not consult 
them, especially those who were isolated and vulnerable. They actively approached this 
group to prevent crisis situations: 
‘I worry more about the people who don’t come to see me than about those who do. Then I 
go along to see them and say: “I haven’t seen you for a while. Are you OK?”’ 
(Male, focus group 2, general GP).
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The GPs also considered older people who were single or recently widowed to be vul-
nerable. Some noted mortality dates in their agenda and visited widows/widowers on 
appropriate days. Single older people were considered susceptible for social isolation: 
‘… but the most important criterion is whether or not they live alone. We tend to keep a 
special eye on these people.’
(Male, focus group 3, general GP).
Other target groups were those with a low socioeconomic status and ethnic minor-
ity groups: these lacked health education more often and belonged to the vulnerable 
group because they were at high risk of developing health problems. This could be a 
result of it being difficult to give lifestyle advice due to language problems: 
‘Another group are the elderly immigrants with communication problems. So one is already 
satisfied if you’re just able to arrange basic care for them, but once you start to explain what 
they could change to make things better for themselves, that’s when the misunderstandings 
start. That makes things really difficult, so then you settle for less.’ 
(Male, focus group 1, GP with special interest). 
Alternatively, when some individuals become more vulnerable, their already disadvan-
taged social position worsens, leading to more problems such as isolation and multi-
morbidity: 
‘When I look at my own patients I see very many “lost” elderly persons … they already have 
a disadvantaged position, and the older they get, the greater the disadvantage becomes … 
more isolation and, of course, much more morbidity and comorbidity.’
(Male, focus group 6, GP with special interest).
Content of preventive care 
For both groups of patients – those with high levels of vitality and those who were vul-
nerable – physical activity was frequently mentioned as an important way to maintain 
or improve their state of health and functioning: 
‘Well, keeping mobile plays a major role in staying healthy. If you just sit and stop moving 
and if you’re overweight, then you’ll never start moving again.’
(Male, focus group 1, GP with special interest).
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Furthermore, according to the GPs, the content of preventive care should differ between 
both groups. In those with high levels of vitality, cardiovascular risk management was 
considered the most important topic: 
‘For the active 60-plussers, I can imagine that stroke prevention is a much more important 
item for them.’ 
(Male, focus group 6, GP with special interest).
Some GPs carried out a cardiovascular health check on request and a few routinely of-
fered such checks to all older persons above, for example, the age of 60 years.
In the population that was considered to be vulnerable, preventive care was mainly 
aimed at quality of life. Prevention of social isolation and functional decline was con-
sidered important, with hearing/visual impairment, cognition, depressive symptoms, 
mobility, prevention of falls, and nutrition being the main topics:
‘Concerning prevention, I think we have to closely monitor how well the elderly are able see 
and hear … if that ability starts to deteriorate I’d like to check it … just to make sure that 
they can still do the few things that make life enjoyable for them … like being able to write 
and read.’
(Male, focus group 2, general GP).
DISCUSSION
Summary 
According to the GPs in this study, the need for preventive care depended on the level 
of patients’ vitality, as perceived by the GP. As such, the focus of preventive care should 
differ between older people with high levels of vitality and those who are vulnerable. A 
conceptual model of preventive care for older people was constructed, showing the dif-
ference in GPs’ perspectives towards these groups. According to this model, preventive 
care comprises five dimensions (aim of care, concept of care, initiator, target groups, and 
content of care); when older people become more vulnerable, the scope of preventive 
care shifts within these five dimensions.
In general, GPs appeared to be more focused on preventive care for people who were 
vulnerable than for those with high levels of vitality. They expected most benefits of 
preventive care to be gained by allowing those who were vulnerable to live as indepen-
dently as possible and by preventing their functional decline. For the population with 
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high levels of vitality, the GPs restricted their role to the traditional one of preventing 
diseases and injuries, for example, by applying cardiovascular risk management. GPs 
assumed that people without a perceived need for help were not sufficiently motivated 
to adhere to preventive advice; their doubt about the value of their advice suggests that 
GPs are making judgments about people’s risks and their ability to change, which might 
not be appropriate.
Strengths and limitations 
Focus group discussions were considered to be the preferred way to explore the percep-
tions of GPs regarding preventive care for older people. With a systematic approach, 
an analytical framework was developed that was discussed by the researchers until 
consensus was reached. To the authors’ knowledge, this is the first study to examine the 
attitudes of GPs towards preventive care for older people.
A possible limitation of this study is that clear definitions of older people who were 
vulnerable, or had high levels of vitality, were not specified; however, during the discus-
sions there was no confusion about these two categories of older people. In general, 
GPs have an internalised concept of ‘vitality’ and ‘vulnerability; those who are vulnerable 
are characterised by increased prevalence of diseases and disorders, a poorer prognosis, 
disability of various kinds, and multiple simultaneous problems.15,16 Furthermore, the 
level of vitality is a continuous scale and the perspectives of the GPs seemed to vary 
along this. The majority of people will be somewhere between these two extremes.
Other potential weaknesses are that only one national health system was investigated, 
and health professionals in no discipline, other than general practice, were interviewed. 
Furthermore, the GPs volunteered to participate and only their opinions, not their daily 
practices, were investigated.
Comparison with existing literature 
Much research has shown that for older people living in the community, a systematic 
screening approach is not effective for highly prevalent disorders.7,17–22 The current study 
confirms this finding: GPs stated that preventing or postponing disability in people who 
are vulnerable needs an individualised approach rather than a systematic screening ap-
proach. However, according to Nielen et al, GPs have a positive attitude towards primary 
prevention of cardiovascular diseases if detection focuses on the group of patients at 
risk.23 The discussions in the focus groups also show that a standardised approach for 
topics such as cardiovascular risk management can be useful for people who have high 




How to identify and classify older people into those who are vulnerable and those who 
have high levels of vitality were not discussed in the focus groups. As GPs want to apply 
different preventive care to these groups, the current study suggests that it is important 
for preventive care to develop a tool to identify these groups of older people.24,25 
Phelan et al described that older persons from an ethnic minority and those with a low 
socioeconomic status are at higher risk for diseases and disorders, and do not derive 
equal benefit from the current capacity to control disease and death.26 GPs in this study 
were aware of these higher risks and the need for a more individualised proactive ap-
proach, but described difficulties in implementing this. It would seem that more effort 
needs to be put into preventive care for these groups, even when the approach for older 
people who are vulnerable is applied to them.
Implications for practice and research 
This study’s findings are based on GPs’ reported behaviour; the extent to which this mir-
rors actual behaviour remains a topic for further empirical research. In addition, more 
research is needed into the way that GPs assess the vitality of older people in practice 
and the effects of those assessments on their actual behaviour and the care outcomes.
This study highlights the need for more research on the ways in which preventive care 
for older people who are vulnerable and those who have high levels of vitality can be 
improved, focusing on ethnic minorities and people with a low socioeconomic status. 
This relies on being able to define those who are vulnerable and those with high vitality 
levels; this distinction needs to be clarified in future research.
To verify this study’s findings, other studies need to be undertaken in order to explore 
how the model fits in with the perspectives of other GPs and in other countries. In addi-
tion, the perspective of older patients should be addressed. Insight into both viewpoints 
will help negotiate care goals that result in shared decision making that truly is shared 
between the GP and the patient.
In the opinion of GPs, preventive care for older people who have high levels of vitality 
can follow a standardised approach; such care for people who are vulnerable, however, 
needs an individualised approach to prevent functional decline and to allow them to 
live as independently as possible for as long as possible.
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Prevention of disability is an important aim of healthcare for older persons. Selection of 
persons at risk is a first crucial step in this process.
Objectives
This study investigates the predictive value of multimorbidity for the development of 
disability in the general population of very old people and the role of cognitive impair-
ment in this association.
Design
The Leiden 85-plus Study (1997–2004) is an observational prospective cohort study with 
5 years of follow-up.
Setting
General population of the city of Leiden, The Netherlands.
Subjects
Population based sample of 594 participants aged 85 years.
Methods
Disability in activities of daily living (ADL) was measured annually for 5 years with the 
Groningen Activity Restriction Scale (range 9–36, 9=optimal). Multimorbidity is defined 
as the presence of two or more chronic diseases at age 85 years. Cognitive function was 
measured at baseline with the mini-mental state examination (MMSE).
Results
At baseline participants with multimorbidity had higher ADL disability scores compared 
with those without [median 11 inter-quartile range (IQR 9–16) versus 9 (IQR 9–13) ADL 
points, Mann–Whitney U test p <0.001]. Stratified into four MMSE groups, ADL disability 
increased over time in all groups, even in participants without multimorbidity (p trend 
<0.001). Multimorbidity predicted accelerated increase in ADL disability in participants 
with MMSE of 28–30 points (n=205, 0.67 points/year, p <0.001), but not in participants 
with lower MMSE scores (all p >0.100).
Conclusion
The predictive value of multimorbidity for the increase in ADL disability varies with 
cognitive function in very old people. In very old people with good cognitive function, 
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multimorbidity predicts accelerated increase in ADL disability. This relation is absent in 
very old people with cognitive impairment.
KEY POINTS
· The predictive value of multimorbidity for the increase in disability in ADL varies 
with cognitive function.
· Multimorbidity does not predict accelerated increase in disability in ADL in older 
persons with cognitive impairment.
· Only in older persons with good cognitive function, multimorbidity predicts acceler-
ated increase in disability in ADL.
· For selection of high-risk patients, multimorbidity can be used only in those older 




The aim of preventive programmes for older people is to enable them to live as inde-
pendently as possible for as long as possible. For these programmes instruments are 
needed to identify older people at high risk to develop disability in the near future. 
When such instruments are available, older people can pro-actively be approached to 
prevent increase in disability.
It is known that chronic diseases1-7 and multimorbidity6-8 are strongly related with dis-
ability. However, most of these studies incorporated cognitive impairment or dementia 
in their multimorbidity scores. Because earlier studies showed strong associations 
between cognitive function and disability,2-4,6-13 the predictive value of multimorbidity 
for disability may differ between persons with and without cognitive impairment.
Therefore, we studied the predictive value of multimorbidity for the increase in disability 
in activities of daily living (ADL) in older persons with and without cognitive impairment.
METHODS
Setting and study population
The Leiden 85-plus Study is an observational population based prospective follow-up 
study of 85-year-old inhabitants of Leiden (The Netherlands). Between September 1997 
and September 1999, all inhabitants of Leiden who reached the age of 85 years were 
invited to participate in the study. 
Participants were followed for 5 years until the age of 90 years or until death. Date of 
death was obtained from the municipality. All participants were visited annually at their 
place of residence where face-to-face interviews were conducted, cognitive testing was 
performed, and disabilities in basic ADL were measured. 
All participants gave their informed consent; for those with severe cognitive impair-
ment, informed consent was obtained from a proxy. The Medical Ethics Committee of 
Leiden University Medical Centre approved the study. For the present study, participants 
with missing ADL measurements at baseline and participants with missing information 
on the presence of two or more chronic diseases at baseline were excluded.




Information on the presence of chronic diseases at baseline was obtained from the par-
ticipant’s general practitioner (GP), nursing home physician and/or pharmacy records. 
We included common chronic diseases in the analyses, which are commonly used in 
multimorbidity scores:14,15 arthritis, chronic obstructive pulmonary disease (COPD), dia-
betes mellitus, heart failure, stroke, Parkinson disease, depressive symptoms reported in 
the previous year, and history of cancer or myocardial infarction. COPD was considered 
present when lung medication [Anatomical Therapeutic Chemical (ATC) code R03] was 
used at age 85 years. Multimorbidity was defined as the presence of two or more of the 
nine chronic diseases investigated. 
Cognitive function was assessed with the mini-mental state examination (MMSE), with 
scores ranging from 0 to 30 (=optimal function)16 and was stratified in four groups: 
MMSE score <19 points (severe cognitive impairment), 19–23 points (moderate cogni-
tive impairment), 24–27 points (mild cognitive impairment) and 28–30 points (optimal 
cognitive function).
Outcome
Disability in basic ADL was determined with the Groningen Activity Restriction Scale, 
which assesses an individual’s competence in the following nine basic activities: walk 
inside, get up out of bed, get into and out of a chair, visit the toilet, wash hands and 
face, wash body, dress and undress, eat and drink and make breakfast.17,18 Questions 
are phrased: “Can you, fully independently,…?”. Answers range from “Fully independently, 
without any difficulty” (1 point) to “Not fully independently, only with someone’s help” (4 
points). The total ADL disability score ranges from 9 to 36.
Data analysis
In the cross-sectional analysis, median scores of ADL disability at age 85 years between 
participants were compared using the Mann–Whitney U test.
Prospectively, the relation between individual chronic diseases and multimorbidity at 
baseline and changes in ADL-disability scores over time were analysed with linear mixed 
models. Each linear mixed model included the individual disease a term for time, and 
a term for the interaction between disease and time. The results of the linear mixed 
models are as follows: the effect of time on disability in ADL reflects the annual change 
in ADL disability in those without the disease, and is presented as basic annual change in 
ADL disability score. The interaction of an individual chronic disease and time reflects the 
44
Chapter 3
additional annual change in ADL disability for those with the disease and is presented as 
additional annual change in ADL disability score.
To assess the influence of cognitive impairment, participants were stratified into four 
groups according to their baseline MMSE score (0–18, 19–23, 24–27 and 28–30)19 and 
the predictive effect of multimorbidity on changes in disability in ADL were examined 
separately in these four groups.
Data were analysed using SPSS 16.0 (Chicago, IL, USA).
RESULTS
Study population
Between September 1997 and September 1999, 705 inhabitants of Leiden reached the 
age of 85 years and were eligible for participation in the study. A total of 14 persons 
died before enrolment in the study, 92 declined to participate, no ADL measures were 
available for two persons, and for three persons information on the presence of two 
or more chronic diseases was missing. Therefore baseline data were available for 594 
participants. Appendix 1 shows the numbers of participants at the start of the study and 
annually over the 5-year follow-up period.
Cross-sectional analysis
Table 1 presents the baseline characteristics, the prevalence of the investigated chronic 
diseases, and the prevalence of multimorbidity among the participants at age 85 years. 
In total, 34% of the participants were male. The prevalence of multimorbidity was 39%. 
Arthritis was the most common chronic disease (33%).
At baseline, participants with arthritis, depressive symptoms, diabetes mellitus, stroke 
and Parkinson disease had higher scores of ADL disability than participants without 
these diseases (Appendix 2). The greatest differences in median ADL disability scores 
between participants with and without an individual chronic disease were seen for Par-
kinson disease (19 versus 10 points, p <0.001) and stroke (15 versus 10 points, p <0.001). 
Participants with multimorbidity had higher ADL disability scores compared with those 
without multimorbidity (11 versus 9 points, p <0.001).
At baseline, highest ADL disability scores were found in participants with an MMSE 
score <19 (Figure 1). In the groups with MMSE scores of 19–23, 24–27 and 28–30, higher 
baseline ADL disability scores were found for participants with multimorbidity than for 
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participants without multimorbidity (all p ≤0.010). However, in subjects with an MMSE 
score <19, no differences in ADL disability scores were found between participants with 
multimorbidity and those without multimorbidity (median ADL disability scores: 19 
versus 19 points, p=0.950).
Prospective analyses
Appendix 3 presents the relation of individual chronic diseases and multimorbidity 
with additional annual changes in ADL performance. In participants without any of the 
investigated chronic diseases, the basic annual change in ADL disability score was 1.2 
points per year (95% CI 1.0–1.4, p <0.001, data not shown). Depressive symptoms, heart 
failure, myocardial infarction and stroke predicted an additional annual change in ADL 
disability score during follow-up. Other individual chronic diseases did not predict an 
additional annual change in ADL disability score (all p >0.100). Participants with mul-
Table 1. Baseline characteristics of the study population at age 85 years (n=594a).
n %
Sociodemographic characteristics
Sex, male 201 34
Low level of education  – primary school only 383 65
Prevalence of individual chronic diseases
Arthritis 193 33
Depressive symptoms 125 21
History of cancer 104 18
Diabetes mellitus 86 15
Heart failure 75 13
COPD 70 12
Myocardial infarction 63 11
Stroke 61 10
Parkinson disease 15 2.5
Total number of chronic diseases 
None 147 25
One 213 36
Two or more (multimorbidity) 234 39
Classification in the mini-mental state examination (MMSE)
MMSE <19 pts 97 16
MMSE 19-23 pts 85 14
MMSE 24-27 pts 207 35
MMSE 28-30 205 35
amissing data in n=0 to n=11 per disease; of 568 participants the data on chronic diseases were complete.
COPD = chronic obstructive pulmonary disease
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timorbidity had an accelerated progression of ADL disability over time compared with 
those without multimorbidity: additional annual change 0.42 points (95% CI 0.21–0.63, 
p <0.001).
The effect of cognitive function on the predictive value of multimorbidity for disability 
in ADL was investigated by stratifying the participants into four groups according to 
their MMSE scores at baseline (Figure 2; Appendix 4). In all MMSE groups, ADL disabil-
ity increased over time, independent of the presence of multimorbidity (basic annual 
change, p for trend <0.001).
Multimorbidity was associated with an additional annual change in ADL disability of 
0.67 points (95% CI 0.39–0.95, p <0.001) in subjects with an MMSE score of 28–30. In 
participants with an MMSE score <28, multimorbidity did not predict the change in ADL 



































Figure 1. ADL disability scores dependent on the presence of multimorbidity at age 85 years stratified for 
cognitive function.
Data were presented as medians and corresponding inter-quartile ranges, p-values estimated with the 
Mann-Whitney U test; ADL, activities of daily living; MMSE, mini-mental state examination.




This population-based study of very old people demonstrates that disability in ADL 
increases over time in older persons of the general population. Multimorbidity only pre-
dicted accelerated increase in disability in ADL in older people with an optimal cognitive 
function (MMSE score ≥28 points). In persons with lower MMSE scores, this relation was 
not observed.
Our findings are in agreement with earlier studies showing that both cognitive impair-
ment and multimorbidity are associated with the development of disability in ADL in 
older persons.9-11,13,15,20 However, these studies did not report that this relation is only 
present in older people with MMSE scores ≥28 points. A possible explanation for these 
findings is that the effect of cognitive impairment on ADL performance overwhelms the 
effect of multimorbidity. Another possible explanation is the possibility that cognitive 
performance at the age of 85 years is a marker for the total health condition, with a 
high sensitivity to detect detrimental effects on ADL disability. In persons with cognitive 
impairment, we found large basic annual changes in ADL disability score, indicating 



































MMSE <19 with multimorbidity (n=38)
MMSE <19 without multimorbidity (n=59)
MMSE 28-30 with multimorbidity (n=70)
MMSE 28-30 without multimorbidity (n=135)
Figure 2. Changes in ADL-disability points over time depending on multimorbidity in participants from 
age 85 years onwards, for strata of cognitive function.




Our study has several strengths. The population-based setting and almost complete 
follow-up of the participants allow to generalise the conclusions to older people (aged 
85 years and over) in the general population. It is important to study the development 
of disability in ADL in old age, because the very old are the fastest growing segment of 
the general population21 and the prevalence of disability in ADL increases with age.12,22,23 
Therefore, disability in ADL in old age can have a significant effect on quality-of-life, 
healthcare needs and costs in our ageing society. Furthermore, the study stratified on 
cognitive function, allowing to investigate the predictive value of multimorbidity for 
disability in ADL at different levels of cognitive function.
A possible limitation of the present study is that we used a selection of only nine diseases, 
as diagnosed by physicians. The prevalence of multimorbidity might have been different 
when other chronic diseases had been included, or when more specific diagnostic tests 
had been used. In addition, we did not take the severity of the chronic diseases into ac-
count. However, our approach of multimorbidity, by using only data of the GPs, nursing 
home physicians and pharmacy records, reflects clinical practice and similar systems of 
adding individual diseases have been applied in many other studies.8
Clinical implications and future research
The most important clinical implication is that multimorbidity can only be used as a 
predictor for disability in ADL in older people with optimal cognitive function. Older 
people with an MMSE score less than 28 are at the highest risk for disability in ADL. 
However, multimorbidity is no longer an additional predictor of disability in ADL in this 
group. Preventive programmes to promote older people to live as independently as pos-
sible may use a two-stage screening test, which contains MMSE screening as a first step 
and multimorbidity screening as the second, to select older people at risk for disability.
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Appendix 1. Number of participants in the Leiden 85-plus Study at age 85 years (baseline) and annual 
follow-up measurements
*missing ADL measures at age 86 years: n=3
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Appendix 3. Additional annual change in ADL disability depending on chronic diseases in 
participants from age 85 years onwards.
Estimated points ADL disability 
(SE)
p-value
Individual chronic diseases 
Arthritis -0.17 (1.1) 0.103
Depressive symptoms 0.42 (0.13) 0.001
History of cancer -0.14 (0.15) 0.330
Diabetes mellitus 0.08 (0.16) 0.611
Heart failure 0.69 (0.18) <0.001
COPD 0.12 (0.18) 0.489
Myocardial infarction 0.42 (0.19) 0.028
Stroke 0.95 (0.19) <0.001
Parkinson disease -0.37 (0.38) 0.333
Multimorbidity 0.42 (0.11) <0.001
Estimated by linear mixed models; ADL = activities of daily living,  COPD = chronic obstructive 
pulmonary disease





n ADL disability p-value
Individual chronic diseases
Arthritis 193 11 (9-15) 399 10 (9-15) 0.024
Depressive symptoms 125 10 (9-16) 458 9 (10-14) 0.013
History of cancer 104 9 (9-13) 487 10 (9-15) 0.100
Diabetes mellitus 86 11 (9-17) 504 10 (9-14) 0.001
Heart failure 75 10 (9-17) 517 10 (9-14) 0.092
COPD 70 10 (9-14) 524 10 (9-15) 0.683
Myocardial infarction 63 10 (9-15) 529 10 (9-15) 0.779
Stroke 61 15 (10-29) 531 10 (9-13) <0.001
Parkinson disease 15 19 (10-33) 579 10 (9-14) <0.001
Multimorbidity 234 11 (9-16) 360 9 (9-13) <0.001
Data presented as medians and corresponding interquartile ranges, p-values estimated with the Mann-
Whitney U test; ADL = activities of daily living, COPD = chronic obstructive pulmonary disease
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Appendix 4. Annual changes in ADL disability points depending on multimorbidity in 
participants from age 85 years onwards, stratified for cognitive function.
Basic annual change Additional annual change for pts with 
multimorbidity
Estimated points ADL 
disability
p-value Estimated points ADL 
disability
p-value
   MMSE < 19 2.4 <0.001 -0.21 0.623
   MMSE 19-23 1.9 <0.001 -0.18 0.597
   MMSE 24-27 1.2 <0.001 0.26 0.101
   MMSE 28-30 0.68 <0.001 0.67 <0.001
Estimated by linear mixed models
ADL = activities of daily living, MMSE = Mini-Mental State Examination
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In clinical practice, general practitioners (GPs) appeared to have an internalized concept 
of ‘vulnerability’. This study investigates the variability between GPs in their vulnerability-
assessment of older persons.
Methods
Seventy-seven GPs categorized their 75-plus patients (n=11392) into not vulnerable, 
possibly vulnerable and vulnerable patients. GPs personal and practice characteristics 
were collected. From a sample of 2828 patients the following domains were recorded: 
sociodemographic, functional [instrumental activities in daily living (IADL), basic activi-
ties in daily living (BADL)], somatic (number of diseases, polypharmacy), psychological 
(Mini-Mental State Examination, 15-item Geriatric Depression Scale; GDS-15) and social 
(De Jong-Gierveld Loneliness Scale; DJG) . Variability in GPs’ assessment of vulnerability 
was tested with mixed effects logistic regression. P-values for variability (pvar) were cal-
culated by the log-likelihood ratio test.
Results
Participating GPs assessed the vulnerability of 10361 patients. The median percentage 
of vulnerable patients was 32.0% (IQR 19.5 to 40.1%). From the somatic and psychologi-
cal domains, GPs uniformly took into account the patient characteristics ‘total number of 
diseases’ (OR 1.7, 90% range=0, pvar=1), ‘polypharmacy’ (OR 2.3, 90% range=0, pvar=1) and 
‘GDS-15’ (OR 1.6, 90% range=0, pvar=1). GPs vary in the way they assessed their patients’ 
vulnerability in the functional domain (IADL: median OR 2.8, 90% range 1.6, pvar <0.001, 
BADL: median OR 2.4, 90% range 2.9, pvar <0.001) and the social domain (DJG: median OR 
1.2, 90% range=1.2, pvar <0.001). 
Conclusions
GPs seem to share a medical concept of vulnerability, since they take somatic and 
psychological characteristics uniformly into account in the vulnerability-assessment 
of older persons. In the functional and social domains, however, variability was found. 
When more uniformity could be achieved vulnerability assessment by GPs might be a 
promising instrument to select older people for geriatric care.
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INTRODUCTION
In aging societies the prevalence of vulnerability increases.1 The vulnerable older popu-
lation is described as the group of older people that presents the most complex and 
challenging problems to physicians and other healthcare professionals. Older persons 
often require geriatric care.2 Vulnerability is a term widely used in discussions on older 
people, in policy documents and in daily care. The term vulnerability indicates a hetero-
geneous group of older people with multiple chronic conditions and/or loss of function 
in one or more domains (e.g. functional, somatic, psychological and social domains).3;4 
Although various tools to screen for manifestations of vulnerability have been devel-
oped,5-11 no standardized and valid method to assess vulnerability is currently available. 
Nevertheless, physicians, especially general practitioners (GPs), appear to be able to 
work with an implicit concept of vulnerability.12;13 
However, it is unknown whether these implicit concepts of vulnerability are uniform. 
GPs may share a unique perspective on what defines vulnerability, but may also have 
distinct perspectives on vulnerability. If and when the vulnerability concepts of GPs 
appear to be identical, assessment by GPs can be a promising instrument to select 
older people for specific geriatric care, because such assessment is relatively simple, 
fast and inexpensive. Therefore, the present study investigates the variability between 
GPs in their vulnerability assessment of older people, to determine whether GPs share a 
uniform concept of vulnerability. 
MATERIALS AND METHODS
Study design and recruitment
The present analysis is embedded in the Integrated Systematic Care for Older People 
(ISCOPE) study, a cluster-randomized controlled trial to investigate the effect of pro-
active care for patients aged 75 years and over. During the inclusion period (September 
2009-September 2010), all patients aged ≥75 years in the participating practices received 
an invitation (by mail) from their GP to participate in the study. Excluded from the study 
were persons with a terminal illness or a life expectancy of ≤3 months. Participants were 
asked to complete a postal screening questionnaire for complex health problems on 
four domains of health (functional, somatic, psychological and social); the questionnaire 
was sent together with the invitation. Written informed consent was obtained from all 
participants. Based on the outcomes of the questionnaire, a random sample of the study 
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population was interviewed at home to obtain baseline data on sociodemographic, 
functional, somatic, psychological and social characteristics. 
The Medical Ethical Committee of the Leiden University Medical Center approved the 
study. The study was registered in the Netherlands Trial Register (NTR1946).
Primary outcome
Before sending the questionnaires to the patients, GPs were asked to assess the vul-
nerability of all their patients aged ≥75 years in three categories: i) not vulnerable, ii) 
possibly vulnerable, and iii) vulnerable. Since our goal was to assess patient vulnerability 
as defined by the GPs themselves, GPs were not provided with a specific definition of 
vulnerability. Instead, they were asked to indicate ‘in their opinion’ which of their pa-
tients were considered vulnerable in the context of this study.
Determinants
GP characteristics
From all GPs we collected information on personal characteristics (sex and age), practice 
characteristics [practice type (single-handed or group), urbanization level (rural or 
urban)] and characteristics of their older patients (number of patients aged ≥75 years, 
median age of patients, and percentage of males).
Patient characteristics
From interviews during home visits we obtained information on sociodemographic 
characteristics (age, sex, income, living situation and home situation). In addition, the 
presence of problems in four domains of health was assessed with questionnaires. 
In the functional domain, disability was assessed with the Groningen Activity Restric-
tion Scale (GARS) questionnaire14;15 which assesses disabilities in competence in nine 
instrumental activities in daily living (IADL) and in nine basic activities in daily living 
(BADL). Scores on the IADL and BADL range from 9-36 points with higher scores indicat-
ing poorer performance.
In the somatic domain information was assessed on self-reported polypharmacy (i.e. 
taking at least four drugs) and on the medical history covering 17 diseases: diabetes 
mellitus, heart failure, obstructive lung disease, incontinence, arthritis, osteoporosis, 
dizziness and falls, prostate problems, cognitive decline, hearing disorder, visual disor-
der and (a history of ) stroke, malignancy, fracture, myocardial infarction, depression and 
anxiety. 
Variability in vulnerability assessment
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In the psychological domain cognitive function was evaluated with the Mini-Mental 
State Examination (MMSE);16 scores range from 0-30 points with lower scores indicating 
poorer cognitive performance. Depressive symptoms were assessed with the 15-item 
Geriatric Depression Scale (GDS-15)17 which is specifically developed to screen for de-
pressive symptoms in older people; scores range from 0 (optimal) to 15 points. 
In the social domain, the De Jong-Gierveld Loneliness Scale (DJG) was used to assess 
feelings of loneliness, with higher scores (range 0-11) indicating more severe loneli-
ness.18;19 The GDS-15 and the DJG were restricted to those with a MMSE score of 19 or 
higher.
Statistical analysis
To describe the GPs’ personal/practice characteristics and patient populations, the 
median and interquartile range (IQR) was calculated of their total population aged ≥75 
years. 
For the analysis of vulnerability, the assessments by GPs were dichotomized into ‘not/
possibly vulnerable’ and ‘vulnerable’. The outcome ‘unknown’ (2.6% of the total popula-
tion) was handled as missing data. 
In the populations assessed as ‘not/possibly vulnerable’ or ‘vulnerable’ the association 
between GP characteristics and percentage of vulnerable older persons per GP was ex-
amined. The median percentage (IQR) of vulnerable older persons per GP characteristic 
was calculated and differences analyzed with the Mann-Whitney U-test. To describe 
the characteristics of the sample that was visited at home, characteristics of the ‘not/
possibly vulnerable’ and ‘vulnerable’ persons were compared by testing differences in 
medians (IQR) for continuous variables with the Mann-Whitney U-test, and differences 
in proportions for dichotomous variables with Pearson’s chi-square test. 
To investigate the association between patient characteristics and the patient’s chance to 
be assessed as vulnerable, we applied mixed effects logistic regression on the participants 
visited at home and who were assessed as ‘not/possibly vulnerable’ or ‘vulnerable’. To 
adjust for the intra-class correlation within the practices a random intercept was used. 
The strength of an association was expressed by the odds ratio (OR) for dichotomous 
variables and by the OR per standard deviation (SD) for continuous variables. If one GP 
gives more weight to a characteristic than another GP, the ORs will vary between GPs. To 
investigate whether the OR for a certain characteristic varies between GPs, a subsequent 
analysis was performed in which we extended the random intercept model with an extra 
random term for that characteristic, thereby allowing that every GP has his/her own OR. 
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The model assumes a lognormal distribution for the GP-specific ORs. The median and 90% 
reference interval of this distribution were estimated. The reference interval runs from 
the 5th to the 95th percentile of the distribution and contains the ORs of 90% of the GPs, 
thereby serving as a characterization of the variability between GPs in the weight they 
attribute to a patient characteristic in assessing vulnerability. If the GPs do not vary in their 
assessment, their ORs will be the same and there will be no range around the median OR. 
If the GPs vary in their assessment and the range includes OR=1, some GPs will weigh a 
patient characteristic in a direction opposite to that of other GPs. P-values for variability 
(pvar) are calculated with the log-likelihood ratio test.
All analyses were performed with IBM SPSS Statistics version 20.
RESULTS
Study population and vulnerability assessment
In total, 77 GPs in 55 participating general practices worked for 11392 registered pa-
tients aged 75 years and over. Table 1 presents the baseline characteristics of these 77 
GPs. Their median age was 51.4 (IQR 43.1 to 57.1) years and 46 (59.7%) were male. The 
majority of the GPs (77.9%) worked in an urban environment. The number of registered 
patients aged ≥75 years per GP ranged from 12 to 479 with a median of 131 (IQR 66 
to 210). Of the 11392 eligible patients, the GPs completed the assessment for 10361 
Table 1. Personal and practice characteristics of GPs (n=77) and the characteristics of their 
registered population aged 75 years and over.
 n (%) or median (IQR)
Characteristics of general practitioner (n=77)
Age in years 51.4 (43.1-57.1)
Sex (male) 46 (59.7)
Environment (urban) 60 (77.9)
Type of practice (single-handed) 24 (31.2)
Characteristics of the population per GP
Number of persons aged 75 years and over 131 (66-210)
Median age of the population 80.8 (79.8-82.1) *
Percentage male in the population aged 75 years and over 36.4 (31.9-40.0)†
Percentage vulnerable older persons‡ 32.0 (19.5-40.1)†
*median (IQR) of the median ages per GP-population
†median (IQR) of the percentages per GP-population
‡calculated for 10361 people who were assessed by the GP as not vulnerable/possibly vulnerable/
vulnerable
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patients. Of the latter group, 2848 (27.5%) were rated as vulnerable, 2644 (25.5%) as 
possibly vulnerable, and 4869 (47.0%) as not vulnerable. Of the remaining 1031 persons, 
292 were assessed as ‘unknown’ and 739 assessments were missing (reasons for missing: 
53 persons died, 123 persons moved away, 71 persons were sent to a nursing home, 61 
persons were terminally ill, 52 persons were excluded for other reasons, and 379 were 
missing for unknown reason). Overall, the median percentage of vulnerable patients per 
GP was 32.0% (IQR 19.5 to 40.1%), ranging from 2.4% to 81.0%. 
GPs living in an urban environment assessed a higher percentage of their patients as 
vulnerable than GPs in a rural environment (33.3% (IQR 22.1 to 40.9%) vs. 23.6% (IQR 
8.4 to 37.4%), p=0.044). No differences in vulnerability assessment were found for the 
type of practice, for the GPs’ personal characteristics (age and sex) and for the number of 
persons aged ≥ 75 years in their practice (all p>0.05) (Table 2).
Of the 10361 patients assessed by the GPs, a questionnaire was sent to 10078 patients 
(excluding: 48 persons who died, 101 persons too ill, 55 persons in a nursing home, 25 
persons who did not understand Dutch, and 54 persons were excluded by the GP for 
other reasons). Of these, 6518 (64.7%) persons responded to the questionnaire (reasons 
for non-participation: 2690 refused, 813 did not respond, 39 moved away, and 18 for 
other unknown reasons). 
Based on the outcomes of the questionnaire, a sample of 2828 persons was visited at 
home. Table 3 presents the characteristics of these persons of whom 31.6% (n=894) were 
Table 2. Association between characteristics of 77 GPs and the percentage of vulnerable older 
persons per practice (n=10361).
Characteristics of GPs and their practice n Median percentage 
of vulnerable older 
persons (IQR)
p-value*
GPs’ age ≤ 50 years 35 35.7 (23.5-43.2) 0.091
> 50 years 42 28.8 (15.5-38.4)
GPs’ sex Male 46 32.0 (19.7-38.8) 0.705
 Female 31 33.3 (19.1-40.8)
Environment Urban 60 33.3 (22.1-40.9) 0.044
Rural 17 23.6 (8.4-37.4)
Type of practice Single-handed 24 26.2 (10.5-35.7) 0.052
Group 53 33.6 (22.8-40.8)
Total number of 75-plus persons in practice ≤ 130 persons 38 34.2 (22.2-42.9) 0.121




assessed as vulnerable and 68.4% (n=1934) as not/possibly vulnerable. The participants 
assessed as vulnerable were older, i.e. median age 83 years (IQR 80 to 88 years) vs. 81 
years (IQR 78 to 86) (p <0.001) and were more often living in a residential home (15.4% 
vs. 7.8%) (p <0.001). In all health domains (functional, somatic, psychological and social) 
the vulnerable older people had less favorable scores than the not/possibly vulnerable 
persons (all p <0.001).
Table 3. Association between patient characteristics and vulnerability assessment by the GP 
(n=2828).
Vulnerability by GP p-value*
Yes
(n=894)




n (%) or 
median (IQR)
Socio-demographic factors
Age  83 (80-88) 81 (78-86) <0.001
Sex, male 294 (32.9) 598 (30.9) 0.296
Income, low (only state pension)† 146 (16.4) 273 (14.1) 0.116
Living situation, living alone† 580 (64.9) 1204 (62.3) 0.184
Home, residential†  138 (15.4) 150 (7.8) <0.001
Functional domain
IADL† 27 (20-33) 19 (13-25) <0.001
BADL† 11 (9-17) 9 (9-11) <0.001
Somatic domain
Total number of self reported diseases 5 (3-6) 4 (2-5) <0.001
Self reported poly-pharmacy (≥ 4 drugs)† 673 (75.7) 1143 (59.2) <0.001
Psychological domain
MMSE† 27 (24-29) 28 (26-29) <0.001
GDS-15†‡ 2 (1-4) 1 (0-3) <0.001
Social domain
DJG†‡ 3 (1-5) 2 (0-4) <0.001
*Mann-Whitney U-test for continuous variables or Pearson’s chi-square test for dichotomous variables 
IADL = Instrumental Activities in Daily Living, BADL=Basic Activities in Daily Living, MMSE=Mini-Mental 
State Examination,  GDS-15= 15-item Geriatric Depression Scale, DJG= De Jong-Gierveld Loneliness 
Scale
† missing in 1-38 participants
‡not administered in 149 participants






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Variability between GPs in vulnerability assessment
To investigate the variability between GPs in the weight they attribute to a patient 
characteristic in assessing vulnerability, data of the 2828 participants visited at home 
were analyzed (Table 4). 
In the sociodemographic domain, GPs only used age and residential living in their 
vulnerability assessment and differed in the weight they attributed to these factors (me-
dian OR 1.6, 90% range=0.6, pvar <0.001 and median OR 2.7, 90% range=3.2, pvar=0.017, 
respectively). Variability was also found between GPs in the functional domain (IADL: 
median OR 2.8, 90% range=1.6, pvar <0.001 and BADL: median OR 2.4, 90% range=2.9, pvar 
<0.001). No variability was found in the somatic domain (self-reported diseases median 
OR 1.7, 90% range=0, pvar=1, polypharmacy median OR 2.3, 90% range=0, pvar=1). In the 
psychological domain variability was also absent for depressive symptoms (GDS-15: 
median OR 1.6, 90% range=0, pvar=1), but GPs differed in the weight they attributed 
to cognition (MMSE: median OR 1.9, 90% range=0.8, pvar <0.001). In the social domain, 
variability was found between GPs and they also differed in the direction of the associa-
tion with vulnerability: i.e. some GPs gave a positive and others a negative weight to 
loneliness (DJG: median OR 1.2, 90% range=1.2, pvar <0.001). 
DISCUSSION 
Principle findings
This study investigated the variability in vulnerability assessments by GPs. The percent-
age of older patients assessed as ‘vulnerable’ by the GP varied per practice (median 
32.0%, IQR 19.5 to 40.1%, range 2.4 to 81.0%). This variation was not only due to differ-
ences in the patient-populations of the GPs, but also depended on differences in the 
weight GPs attributed to some patient characteristics in the vulnerability assessment. 
All GPs took some somatic and psychological characteristics uniformly into account. In 
the functional and social domains variability was found in the way GPs assessed their 
patients’ vulnerability. 
In the present study, an urban environment was the only practice characteristic that was 
associated with the percentage of vulnerable older persons. However, the environment 
of the GP’s practice can also be considered as a patient characteristic. Apparently, older 
persons living in a city were more likely to be assessed as ‘vulnerable’. 
In the somatic and psychological domains, patient characteristics predicted the vulner-
ability assessment by the GP, and the GPs weighed these patient characteristics almost 
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equally. The formal education of GPs and their corresponding focus on diseases may 
explain these findings. GPs are educated in clinical observation, which mainly takes into 
account somatic and psychological characteristics, as well as age and sex. This study 
shows that (with the exception of sex) GPs almost uniformly attribute predictive values 
to these items; sex did not predict the outcome of the vulnerability assessment and no 
differences were found between GPs. Apparently, sex is not a discriminative factor in the 
vulnerability assessment by GPs.
In the functional domain, although strong predictive values of the patient characteris-
tics were found, GPs differed in the way they used these patient characteristics in their 
assessment. Although GPs are aware of the importance of functional status for vulner-
ability, they might not use a standard approach while taking functioning into account. 
Similar results were found for type of residence: this might be explained by the fact 
that people in residential homes often have a functional impairment. In clinical practice, 
GPs tend to focus on medical problems using a disease model as concept of care. If the 
vulnerability assessment would have been carried out, for example, by nurses (who are 
mainly trained in functional models), it is likely that uniform outcomes will be found 
in the functional domain and variability in the somatic domain. If GPs received more 
training in the use of functional models,20 the differences between them might become 
smaller. 
Finally, in the social domain the loneliness score predicted vulnerability, even though 
GPs varied in the way they took this characteristic into account: i.e. loneliness increased 
a patient’s chance to be assessed as vulnerable by most GPs, whereas some GPs weighed 
loneliness in the opposite direction. Interpretation of this outcome is difficult but might 
indicate that GPs are unaware of patients’ loneliness as measured in the present study; 
this is in line with earlier research indicating that some GPs rarely ask their patients 
about loneliness.21 The impact of the social domain on vulnerability should be explored 
in further studies.
Comparison with existing literature
Various tools have been developed to screen for vulnerability,5-11 but no standardized 
and valid method is available. Knowledge on the prevalence of vulnerability as assessed 
by GPs is currently limited. For example, although Hoogendijk et al. compared clinical 
judgment with several frailty instruments, only one GP was involved.22 To our knowl-
edge, ours is the first study in which several GPs were asked to assess the vulnerability of 
their registered older patients, without imposing a pre-described definition. The present 
study shows that GPs generally share a unique perspective on what defines vulner-
ability in the somatic and psychological domain, but differ in the way they interpret 
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the functional domain. GPs are probably not aware of this phenomenon, because other 
studies report that they consider themselves able to work with an undefined concept of 
vulnerability.12;13 
Strengths and limitations
The present study has several strengths. It is a large population-based study of GPs and 
their registered patients aged ≥ 75 years. Also, because we did not impose a definition 
of ‘vulnerability’, the assessment revealed the GP’s own interpretation of the concept 
of vulnerability. In this study, 77 GPs assessed the vulnerability of almost all of their pa-
tients; therefore, there was no (or minimal) selection of patients in the assessment by the 
GP. Furthermore, GPs were unaware of the outcome of the study measurements because 
they performed the assessments before randomization and before other data were col-
lected. Unfortunately, it was not possible to interview the GPs about the concepts of 
vulnerability they used during their assessments. However, we were able to analyze the 
variability between GPs in the way they weighed the characteristics of their patients. 
In this study the variability between GPs might be an overestimation of the true vari-
ability, because the most obviously vulnerable patients may not have been included 
in our analysis. Variability can also partly be explained by the fact that GPs might not 
have examined all their patients recently. At the moment of assessing their patients’ 
vulnerability, GPs were unable to take all recent changes in patients’ functioning into 
account. Moreover, other patient characteristics that might influence the vulnerability 
assessment may not have been examined. However, the literature does not include any 
other important characteristics that we did not investigate.
Implications and further research
GPs appear to share a medical concept of vulnerability because they take somatic and 
psychological characteristics uniformly into account in the vulnerability assessment; 
however, they differ in the weight they attribute to functional status and loneliness. 
More uniformity might be achieved if GPs received training in the use of a functional 
model as concept of care. The impact of the social domain on vulnerability should be ex-
plored in further studies. More research is needed to compare the outcomes of the vul-
nerability assessment by GPs with those of other tools that measure vulnerability. Such 
analyses may reveal the additional value of screening tools compared to assessment by 
GPs, which is a simple, inexpensive and apparently reliable method. If stratification on 
vulnerability becomes feasible, this will facilitate the selection of older individuals who 
may best benefit from specific geriatric care.
Variability in vulnerability assessment
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To identify appropriate screening conditions, stratified according to age and vulner-
ability, to prevent functional decline in older people.
Design




A multidisciplinary panel of 11 experts.
Measurements
The panelists assessed the appropriateness of screening for 29 conditions mentioned 
in guidelines from four countries, stratified according to age (60–74, 75–84, ≥85) and 
health status (general, vital, and vulnerable) and received a literature overview for each 
condition, including the guidelines and up-to-date literature. After an individual rating 
round, panelists discussed disagreements and performed a second individual rating. 
The median of the second ratings defined the appropriateness of screening.
Results
The panel rated screening to be appropriate in three of the 29 conditions, indicating that 
screening was expected to prevent functional decline. Screening for insufficient physi-
cal activity was considered appropriate for all three age and health groups. Screening 
for cardiovascular risk factors and smoking was considered appropriate for the general 
and vital population aged 60 to 74. Of the 261 ratings, 63 (24%) were classified as uncer-
tain, of which 42 (67%) concerned the vulnerable population. The panelists considered 
conditions inappropriate mainly because of lack of an adequate screening tool or lack of 
evidence of effective interventions for positive screened persons.
Conclusion
The expert panel considered screening older people to prevent functional decline ap-
propriate for insufficient physical activity and smoking and cardiovascular risk in specific 
groups. For other conditions, sufficient evidence does not support screening. Based on 
their experience, panelists expected benefit from developing tests and interventions, 
especially for vulnerable older people.
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INTRODUCTION
The interest in screening community-dwelling older people is increasing,1-4 and several 
guidelines for such screening have been issued.5-13 Screening is a strategy used in a 
population to detect a disease, risk factor, or ailment in individuals with unrecognized 
signs or symptoms. In general, the intention of screening is to identify the screened 
condition early, enabling earlier intervention and management to postpone diseases 
and death, but older people (especially frail older people) do not always benefit from 
screening because of their shorter natural life expectancy and their lack of physiological 
reserve to tolerate the invasive interventions called for after screening.4
For these older populations, screening can have an additional aim. In this age group, the 
aim is also to contribute to healthy aging, which is a prominent theme in current health 
policy.14-17 Healthy aging is not only a matter of maintaining good physical and mental 
health, but also of older people remaining independent and participating in social ac-
tivities. As the general health status of older people declines, values such as functioning 
in daily life and well-being become more important than life expectancy.18 Therefore, it 
was postulated that a screening approach to community-dwelling older people would 
be appropriate if it aimed at preventing and postponing functional decline,19 but current 
screening guidelines tend to ignore this aim. In addition, specific research on screening 
in older people is scarce. Therefore, screening guidelines often have to address a lack of 
age-specific evidence.
In the present study, an expert panel assessed the contribution of screening of com-
munity-dwelling older people to the prevention of functional decline using the RAND/
University of California at Los Angeles (UCLA) appropriateness method.20-22 This method 
was chosen because a preceding literature search showed that the available scientific 
evidence was inconclusive. This RAND/UCLA appropriateness method was specifically 
developed to combine the available scientific evidence with the collective judgment 
of experts. To select conditions for this study, the content of general guidelines and 
protocols on screening and prevention was used. The appropriateness of screening 
the older population to prevent functional decline was assessed for several conditions 
by applying the most frequently used criteria for screening of this older population, 
formulated in 1968 by Wilson and Jungner (Table 1).23 Because the older population is 
heterogeneous, and it was hypothesized that age and vulnerability would be important 





The RAND/UCLA appropriateness method was used.20,22 The method was designed in 
the mid-1980s, primarily as an instrument to enable measurement of the overuse and 
underuse of medical and surgical procedures. Since then, this method has been used 
for many topics and its validity and reliability have been demonstrated in a wide variety 
of medical and preventive procedures that lack a firm evidence base.27-29 For a detailed 
description see Appendix.
Selection of screening conditions and literature review
Guidelines and protocols on screening and prevention were used to select conditions 
for this study. Conditions were selected from three Dutch guidelines and protocols 
on screening and prevention5-7 and from English-language guidelines of five leading 
healthcare institutes in the United States, Australia, and Great Britain.8-13 Two of these 
documents were specifically developed for vulnerable older people,6,10 but none of 
them was specifically aimed at prevention of functional decline.
A screening condition was considered eligible if it was recommended in one or more of 
these guidelines; this resulted in 29 conditions. To compile an overview of the evidence 
for each of these conditions, the guidelines and the literature references on which these 
guidelines were based were collected. For each condition separately, a scientist with 
expertise in the content of that condition was asked to comment on the guidelines 
and reference lists and to add up-to-date information if available. These files, one for 
each condition, formed the evidence package for the expert panel. The panelists used 
the literature overview from the evidence packages and their expertise to weigh the 
evidence for screening of each condition.
To acquire an overview of the differences between the guidelines and protocols, two 
researchers (YD, VvdM) independently divided the screening recommendations of the 
guidelines into the following groups: positive advice for older people in general, positive 
advice for specific groups of older people (people at risk, as defined in the guidelines), 
negative advice, insufficient evidence to give advice, or screening not mentioned in the 
guideline. Any disagreement between the two researchers was settled by consensus 
discussions or by a third party (JG).
Expert panel and rating process
For the panel, 11 experts from disciplines involved in geriatric care and screening were 
recruited from eight university medical centers: seven physicians with scientific exper-
tise, of whom four were general practitioners (JD, JM, HS, AW), two were clinical geriatri-
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cians (SdR, RW), and one was a nursing home physician (KdV); three scientists, of whom 
two were public health scientists (MG, FS), and one was a nursing scientist (MS); and an 
expert from Vilans, a Dutch Knowledge Centre on Ageing (RvO). In brief, the RAND/UCLA 
appropriateness method entails two rounds of independent ratings by panelists, with 
one face-to-face group discussion (supervised by an independent chairman) between 
these rounds.22 The panelists rated the appropriateness of screening for each condition. 
The score of each panelist was equally weighed in the final ratings. One month before 
the meeting, panelists received the evidence packages, definitions of the terms used for 
the procedure, the criteria of Wilson and Jungner,23 and the rating sheets.
In accordance with the RAND/UCLA appropriateness method, the expert panel was 
instructed to weigh evidence and to use their expert opinion for assessment of the 
contribution of screening to the prevention or postponement of functional decline 
for each specific condition. The panelists followed the previously developed criteria of 
Wilson and Jungner for each condition; they investigated whether evidence was present 
to fulfill the criteria for a specific condition, taking their expert opinion about a potential 
benefit into account.
Prevention or postponement of functional decline was defined as supporting the ability 
of older people to function as independently as possible.18 Screening was considered 
appropriate if the health benefits exceed the health risks by a margin that was suffi-
ciently wide to make the procedure worth doing.20,22,30 The expert panel was asked to 
rate each condition for each of the three age groups (60–74, 75–84, ≥85) and for each of 
the three levels of health status (general, vital, and vulnerable).
Table 1. Wilson and Jungner criteria for screening.23
1. The condition sought should be an important health problem
2. There should be an accepted treatment for patients with recognized disease
3. Facilities for diagnosis and treatment should be available
4. There should be a recognizable latent or early symptomatic stage
5. There should be a suitable test or examination
6. The test should be acceptable to the population
7. The natural history of the condition, including development from latent to declared disease, should be 
adequately understood
8. There should be an agreed policy on whom to treat as patients
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relation to possible expenditure on medical care as a whole
10. Case-finding should be a continuing process and not a ‘once and for all’ project
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In the present study, the general population was defined as the overall older popula-
tion. This population was split into a vulnerable population with a high prevalence of 
diseases and disorders, a poorer prognosis, disability of various kinds, multiple problems 
simultaneously, and a vital population that was defined as nonvulnerable.
The rating process resulted in nine ratings per condition. Rating was done on a 1- to 
9-point Likert scale (1 = extremely inappropriate, 5 = uncertain or equivocal, and 9 = ex-
tremely appropriate to screen).
The rating sheets were returned by mail and tabulated, and the results of the first-round 
rating were used to guide a subsequent 2-day face-to-face meeting of all panelists in 
March 2009. At the face-to-face meeting, headed by a moderator experienced in the 
RAND/UCLA appropriateness method (HR),6,31 each panelist received a report of his 
or her own first-round ratings, a frequency distribution, and the median of the whole 
panel. The individual ratings were blinded to other group members. Every condition was 
discussed to identify areas of disagreement, to highlight evidence not cited in the litera-
ture reviews, and to clarify specific definitions or wording of the conditions. In addition, 
panelists could revise existing conditions to better fit their judgment and could propose 
new conditions. The Wilson and Jungner criteria were used as leading principles in the 
discussion. After these discussions, in which the assessment was based on the combina-
tion of evidence and expert opinion, each panelist rerated all of the conditions on the 
1- to 9-point scale. The entire discussion was audiotaped, and two researchers (YD, JG) 
made field notes. After the session, a report was written and sent to the panelists for 
their comments. These documents were used in the analysis to explain the outcomes of 
the ratings.
Appropriateness
The final appropriateness judgments were based on the median panel rating and level 
of disagreement for each condition in the second round, using the following definitions: 
all conditions with a median rating of 7 to 9, rated without disagreement, were classified 
as appropriate; those with a median rating of 1 to 3, rated without disagreement, were 
classified as inappropriate; and those with a median rating of 4 to 6, as well as all condi-
tions rated with disagreement, regardless of the median, were classified as uncertain. A 
condition was considered to be rated with disagreement when at least three panelists 
rated it in the 1 to 3 range, and at least three panelists rated it in the 7 to 9 range.32




The guidelines for screening5-13 showed a great variety of conditions and screening ad-
vice. None of the individual 29 conditions was addressed in all screening guidelines. The 
most frequently advised screening was for smoking status, followed by cardiovascular 
risk factors, malnutrition, and overweight. For abdominal aortic aneurysm, cognitive 
impairment, depression and anxiety, diabetes mellitus, and osteoporosis, the guidelines 
gave conflicting recommendations; some advised screening for these conditions, 
whereas others warned against screening. Table 2 gives an overview of the recommen-
dations in the guidelines; the conditions included in the second rating process are also 
shown.
RAND/UCLA appropriateness method
In the first round with 29 conditions, there was disagreement in 23% (59/261) of the rat-
ings. In the second round, after the face-to-face meeting, the disagreement was reduced 
to 3.4% (9/261). During the discussion sessions, three conditions were dropped because 
they were too difficult to define in an unequivocal way (social well-being, social support, 
and spare time), two conditions were divided into two parts (nutrition into malnutrition 
and undernutrition and burden of the informal caregiver into burden of the screened 
person as informal caregiver and burden of the informal caregivers around the screened 
person). One specification of a subgroup was added to abdominal aortic aneurysm and 
was discussed separately (abdominal aortic aneurysm in (ex-)smoking men). As a result, 
the second round also addressed 29 conditions.
Appropriateness
For the older population in general, screening for insufficient physical activity for all 
three age groups and screening for cardiovascular risk and smoking for aged 60 to 74 
were rated appropriate, indicating that screening was expected to prevent functional 
decline (Table 3). Screening was rated uncertain for hearing impairment (all three age 
groups), colorectal cancer (60–74 and 75–84), the burden of the screened person as 
informal caregiver, smoking status (75–84 and ≥85), cardiovascular risk factors (75–84) 
and abdominal aortic aneurysm in (ex-)smoking men (60–74), indicating serious doubts. 
For all the other conditions, screening of the general older population was considered 
inappropriate.
Influence of vulnerability
Screening for insufficient physical activity was considered appropriate for all older per-
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































appropriate in the vital population aged 60 to 74. Uncertainty (median range: 4–6 or 
disagreement) about the appropriateness was rated in 24% (63/261) of the scores. Of all 
uncertain outcomes, 67% concerned the vulnerable population. The panelists argued 
that lack of sufficient evidence to fulfill the criteria of Wilson and Jungner is mainly due 
to lack of research in this population as such. Based on their expertise in clinical practice, 
they assumed that development of specific tests and interventions for this group may 
generate evidence and will lead to benefits of screening, especially when the screening 
approach is embedded in regular care.
Influence of age
In contrast to expectations, the age category of the persons did not strongly influence 
the ratings of the panel (Table 3). Exceptions to this were cardiovascular screening and 
smoking status (influence of age in all three groups of health status); abdominal aortic 
aneurysm in (ex-)smoking men, colorectal cancer, burden of the screened person as 
informal caregiver (influence of age in the general and vital population); and urinary 
incontinence (influence of age in the vital population). For cardiovascular screening 
of older people, the main problem is lack of a suitable test. The panelists considered 
that Framingham Study scores were not valid for the older age categories because 
these scores do not predict cardiovascular mortality in the oldest old.33 For smoking, 
abdominal aortic aneurysm in (ex-)smoking men, and colorectal cancer, the importance 
of screening declines with increasing age for different reasons (e.g., for smoking, there 
is insufficient evidence for the yield of stopping at older age; for aneurysm, the risk of a 
surgical procedure increases with age; and for colorectal cancer, the natural history at 
older age is unknown, and the risk of surgery increases with age). In contrast, the ap-
propriateness of screening for urinary incontinence and for the burden of the screened 
person as informal caregiver increases with age, mainly because the yield increases.
Reasons for uncertainty and inappropriateness
When the panelists expected benefits of screening according to their expert opinion, 
although evidence was lacking, they rated the condition in the uncertain range. Screen-
ing for a condition was rated in the inappropriate range when evidence from literature 
was against screening or when evidence was lacking and the panelists expected no 
benefit according to their expert opinion. In the panel discussions, the most frequently 
used argument for inappropriateness was lack of evidence for effective interventions 
(Wilson and Jungner criterion 2).23 There was sometimes a perceived lack of a rational 
evidence-based intervention (e.g., dementia, smelling problems), and sometimes it was 
assumed that adherence to advice or treatment after a positive screening would be too 
low on the basis of experience or circumstantial scientific evidence (e.g., urinary inconti-
nence, hearing aid, alcohol abuse). Furthermore, the panel thought some conditions to 
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Table 3. Appropriateness of screening to prevent functional decline in the general older 






Conditions to screen for* 60-74 75-84 ≥ 85+ 60-74 75-84 ≥ 85+ 60-74 75-84 ≥ 85+
At least one rating appropriate
Insufficient physical activity 7 7 7 7 7 7 7 7 7
Smoking status 7 6 4 7 6 4 6 5 3
Cardiovascular risk 7 3D‡ 2 7 5D 2 4D 2 2
At least one rating uncertain
Burden of the screened person as 
informal caregiver
3 4 4 3 4 4 5 5 5
Hearing impairment 4 4 4 2 2 2 5 5 5
Urinary incontinence 3 3 3 3 4 4 5 5 5
Colorectal cancer 5 4 2 6 5 2 3 3 2
Burden of informal caregivers around 
the screened person 
1 2 2 1 1 2 5D 5D 5D
Cognitive impairment / dementia 2 2 2 1 1 1 5 5 6
Depression and anxiety 2 2 2 2 2 2 5 5 5
Functional status 3 3 3 2 2 2 5 5 5
Loneliness 2 2 2 2 2 2 5 5 5
Malnutrition 2 2 2 2 2 2 4D 4D 4D
Pain 2 2 2 1 1 1 5 5 5
Polypharmacy 2 2 2 2 2 2 5 5 5
Undernutrition 3 3 3 2 2 2 5 5 5
Visual impairment 2 2 2 2 2 2 6 6 6
Abdominal aortic aneurysm in (ex-)
smoking males
4 2 2 5 3 2 2 2 1
All ratings inappropriate
Abdominal aortic aneurysm 2 1 1 2 1 1 1 1 1
Alcohol misuse 2 2 2 2 2 2 2 2 2
Chronic kidney disease 2 2 2 2 2 2 3 3 3
Diabetes mellitus 3 3 2 3 3 2 2 2 2
Falls 2 2 2 2 2 2 3 3 3
Skin cancer 1 1 1 1 1 1 1 1 1
Osteoporosis 1 1 1 1 1 1 2 2 2
Overweight 2 2 2 3 3 3 2 2 2
Sleep disorders 2 2 2 2 2 2 3 3 3
Smelling problems 1 1 1 1 1 1 1 1 1
Speech problems 1 1 1 1 1 1 1 1 1
*  Ranked according to appropriateness and alphabetically. 
†  Range: 1-3, inappropriate; range 4-6, uncertain ;  range 7-9, appropriate.




be of insufficient importance (Wilson and Jungner criterion 1) because the prevalence 
was too low to warrant screening (e.g., skin cancer in the Netherlands) or the relevance 
of screening for the condition was not considered to be high enough (e.g., pain and 
sleeping disorders). In general, the panelists expected that people with these problems 
and motivation for subsequent interventions would already be seeking help. For some 
conditions, a suitable test or examination was lacking (Wilson and Jungner criterion 5): 
too many false positives (fecal occult blood test for colorectal cancer) or too many false 
negatives (alcohol abuse, osteoporosis), problems with acceptance of the test (colonos-
copy), or test not validated for screening (De Jong-Gierveld Loneliness Scale).34
DISCUSSION
Principle findings
Despite increasing interest in screening of community-dwelling older people and the 
recommendations in guidelines, the Dutch panel considered screening of only a few 
conditions to be appropriate. Screening for insufficient physical activity to prevent 
functional decline is appropriate for all older persons. Screening for cardiovascular risk 
factors and smoking status are considered useful for the general older population aged 
60 to 74 but not for vulnerable older people in the same age range. There is insufficient 
evidence to support screening for the other investigated conditions.
During the face-to-face meeting, the experts emphasized that an uncertain or inap-
propriate rating does not mean that the condition is irrelevant but that there was 
insufficient evidence to recommend an active screening approach. To conclude that 
screening contributes to the prevention of functional decline, screening must at least 
approximately meet the criteria of Wilson and Jungner. When evidence to fulfill the 
criteria of Wilson and Jungner was lacking or inconclusive, the experts’ opinions about 
a potential benefit to prevent functional decline were taken into account. It was not 
thought that strong evidence supported interventions that merely stimulate well-being 
(e.g., interventions to address loneliness), although based on experience, the panelists 
expected at least some benefit from these interventions.
Vulnerability was considered to be an important factor in the determination of appro-
priateness of screening. For 11 of the 29 conditions, the panelists were uncertain about 
the appropriateness of screening vulnerable older people, whereas they considered 
screening of older persons with good vitality for the same condition to be inappropriate. 
Because of lack of research data on the vulnerable group, the panelists had to rely on 
their expert opinion to rate these screening options. They expect benefit from screening 
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when more tests and interventions are developed for this group. Because the major-
ity of vulnerable older people already receive medical care for their chronic disease(s), 
the panelists expected more benefit from improving regular care than from a separate 
screening program.
Age played a small role during the panel discussions. Appropriateness of screening 
was modified according to age for only six conditions: smoking status, cardiovascular 
risk, abdominal aortic aneurysm in (ex-)smoking men, colorectal cancer, burden of the 
screened person as informal caregiver, and urinary incontinence. A possible explana-
tion for this is the relationship between age and vulnerability, with the latter being the 
discriminating factor in rating.
Some guidelines5,7,11,13 claim that their recommendations are based on the criteria of Wil-
son and Jungner, although there are marked differences between the recommendations 
in these guidelines. A possible explanation for the differences in these guidelines is a dif-
ference in the validity of the guideline procedures. For example, the Vilans guidebook,7 
which contains the most positive advice, is a descriptive protocol of available screening 
conditions for older people rather than an evidence-based screening guideline. Also, 
considerable differences may exist between countries in the interpretation of evidence 
because of cultural differences and differences in healthcare systems, which influence 
recommendations in the guidelines.35 The validity of the guideline processes (e.g., using 
the Appraisal of Guidelines, Research, and Evaluation in Europe (AGREE) instrument)36 
was not formally assessed in the present study, because the main focus was determina-
tion of the appropriateness of screening by the expert panel.
Comparison of the outcome of the RAND/UCLA appropriateness method with the 
recommendations of the various guidelines shows considerable differences between 
guidelines. The panel rating was more in accordance with the European guidelines than 
with the U.S. and Australian guidelines, probably because of an underlying cultural 
difference; (e.g., when evidence is lacking, Dutch healthcare professionals tend to rely 
on the adage primum non nocere, to defend patients from iatrogenic harm). Vulnerable 
older people are at higher risk for expected and unexpected side effects of confirmatory 
testing that follow a screening test and subsequent treatment.4 In addition, organization 
of care and healthcare availability may play a role; all inhabitants in The Netherlands 
have healthcare insurance, and almost everyone is registered with one general practice 
over many years. People aged 75 and older contact their general practitioner more than 
16 times a year,37 which often allows the general practitioner to detect relevant changes 
in and problems with the aging process on a personal level.
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Osteoporosis, for example, is a condition in which these cultural and healthcare differ-
ences played a role in the panelists’ discussions. For osteoporosis, earlier research result-
ed in evidence-based methods to identify risk for osteoporotic fractures and effective 
medications to reduce fractures, but as the U.S. Preventive Services Task Force showed in 
its review of July 2010,38 no trials have directly evaluated screening effectiveness, harms, 
and intervals between screening. This lack of direct evidence leaves room for weighing 
and interpretation, apparently resulting in the overall finding that European guidelines 
contained negative advice to screen for osteoporosis, whereas the non-European guide-
lines recommended screening. In the present study, the panelists considered that, in The 
Netherlands, assessment of osteoporosis was already part of treatment in older people 
after fracture. In people using corticosteroids for a prolonged period, prevention and 
treatment of osteoporosis also form part of the therapeutic plan. This means that the 
high-risk groups are already assessed in the context of “normal” care. Only older people 
without a fracture and without use of corticosteroids are still unscreened. For this low-
risk group, the panelists argued that, although screening for osteoporosis in general 
has not been proven to be effective, screening in this remaining low-risk group will be 
even less effective. Therefore, according to the panelists, there is insufficient evidence 
to support screening for osteoporosis, especially regarding the screening test (too many 
false negatives in this low-risk group; Wilson and Jungner criterion 5).
Strengths and limitations
The present study has several strengths. First, the focus on healthy aging by preventing 
functional decline is relatively new in studies on screening. In this study, the objective 
of screening older people was not primarily to prevent and postpone disease and 
death but rather to support the ability of older people to function as independently 
as possible.18 The results of the study indicate the need for more high-quality studies 
to support the benefit of screening to prevent functional decline. Another strength is 
the multidisciplinary panel, because the composition of the panel is known to influence 
the outcome of the RAND/UCLA appropriateness method.39 Most users of the RAND/
UCLA method recommend using a multidisciplinary panel to better reflect the variety 
of specialties involved in decisions on treatment.22 If another panel in which the com-
position in terms of disciplines is maintained repeats the same procedure, the results 
will be reproduced with a high level of agreement.27,30,40 In the present study, the initial 
disagreement in the first round (23%) meant that the panel composition adequately 
reflected the different opinions about screening in health care. During the discussion, 
all panelists were engaged in a positive-critical way and were willing to change their 
opinion, if necessary.
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One limitation of the present study is the specific Dutch context in which the RAND/
UCLA appropriateness method was used; this might influence generalizability. It would 
be interesting if panels in other countries would replicate this study in order to compare 
the findings.
Another limitation is that it was not feasible to perform exhaustive systematic reviews 
for all 29 conditions for all 10 criteria of Wilson and Jungner. Instead, the literature on 
which the guidelines were based was collected, and experts were invited to complete 
and update these files with recent literature. This practical approach is in accordance 
with the RAND/UCLA appropriateness method.22
Clinical implications and future research
The results of the RAND/UCLA appropriateness method indicate that, according to the 
panelists, only screening of the general older population for insufficient physical activity, 
smoking status, and cardiovascular risk in specific groups is recommended to prevent 
functional decline. The uncertain or inappropriate rating of the remaining screening 
conditions does not mean that the conditions are not relevant but that there is insuf-
ficient evidence to recommend an active screening approach at the population level. 
For the conditions rated uncertain, mostly regarding the vulnerable older population, 
evidence was lacking, although based on their clinical experience, the panelists ex-
pected potential benefit from screening embedded in the regular care for this group of 
older people. It is important in future research to detect effective screening approaches 
and subsequent treatments to maintain functional status and related quality of life for 
this group. Then, screening and monitoring as part of regular care will support healthier 
aging by preventing or delaying functional decline.
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The RAND/UCLA Appropriateness Method was developed in the mid 1980s, as part 
of the RAND Corporation/University of California Los Angeles (UCLA) Health Services 
Utilization Study, primarily as an instrument to enable measurement of the overuse 
and underuse of medical and surgical procedures. In the RAND/UCLA Appropriateness 
Method, the concept of appropriateness refers to the relative weight of the benefits 
and harms of a medical or surgical intervention. An appropriate procedure is one in 
which the expected health benefit exceeds the expected negative consequences by a 
sufficiently wide margin that the procedure is worth doing.
Literature review
The first step in the procedure is to perform a literature review to synthesize the latest 
available scientific evidence on the condition. 
For the current study, conditions were selected from three Dutch guidelines/protocols 
on screening and prevention,2-4 and from English-language guidelines of five leading 
health care institutes in other countries (USA, Australia and Great Britain).5-10 A condition 
was considered eligible to screen for, if it was recommended in one or more of these 
guidelines. For each condition separately, a scientist with expertise in the content of that 
condition was asked to comment on the guidelines and reference lists, and to add up-
to-date information if available. These files, one for each condition, formed the evidence 
package for the panelists.
Developing the rating sheets
The second step in the procedure is to produce rating sheets in the form of a matrix 
which categorizes patients who might have an indication for the procedure in question. 
For the current study, the patients were categorized in the rating sheets in three age 
groups (60-74 years, 75-84 years, and 85 years and older) and in three levels of health 
status (general, vital and vulnerable), which resulted in nine ratings per condition. 
The expert panel
A third step in the process is to compose an expert panel. A panel of experts is identified, 
often based on recommendations from the relevant medical societies. The literature re-
view and the list of conditions, together with a list of definitions are sent to the members 
of this panel. 
For the current study, 11 experts from disciplines involved in geriatric care and screening 
were recruited from all eight university medical centers: general practice, clinical geriat-
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rics, nursing home medicine, public health, nursing science, and an expert from Vilans, 
a Dutch Knowledge Centre on Ageing. One month before the meeting these panelists 
received the evidence packages, definitions of the key terms used for the procedure, the 
criteria of Wilson and Jungner11 as background information, and the rating sheets.
The rating process
The fifth step is the rating by the panelists. For each indication, the panelists rate the 
appropriateness of the procedure. Rating is done on a 1-9 point scale, defined as follows: 
1=extremely inappropriate, 5=uncertain or equivocal, and 9=extremely appropriate to 
screen. The panelists rate each of the indications twice, in a two-round ‘modified Delphi’ 
process. In the first round, the ratings are made individually at home, with no interaction 
among panelists. In the second round, the panelists meet for 1-2 days under the leader-
ship of a moderator experienced in using the method. Each panelist receives a report of 
his/her own first-round ratings, a frequency distribution, and the median of the whole 
panel. The individual ratings are blinded to other group members. Every indication is 
discussed to identify areas of disagreement, to highlight evidence not cited in the litera-
ture reviews, and to clarify specific definitions or wording of the conditions. In addition, 
panelists can revise existing conditions to better fit their judgment as well as propose 
new conditions. After discussing each chapter of the list of indications, they re-rate each 
indication individually. The score of each panelist is equally weighted in the final ratings. 
No attempt is made to force the panel to consensus. Instead, the two-round process is 
designed to sort out whether discrepant ratings are due to real clinical disagreement 
over the use of the procedure (‘real’disagreement) or fatigue or misunderstanding 
(‘artifactual’ disagreement). This rating procedure combined the best available scientific 
evidence with the collective judgment of experts.
In the present study, the expert panel was instructed to assess the contribution of screen-
ing for each specific condition to the prevention or postponement of functional decline. 
The expert panel was asked to rate each condition on a 1-9 point scale (1=extremely 
inappropriate, 5=uncertain or equivocal, and 9=extremely appropriate to screen) for 
each of the three age groups (60-74 years, 75-84 years and 85 years and older) and for 
each of the three levels of health status (general, vital and vulnerable). At the start of the 
face-to-face meeting, each panelist received a report of his/her own first-round ratings, a 
frequency distribution of the ratings of all panelists, and the median of the whole panel 
(Figure 1). During the meeting, each condition was discussed, especially disagreements, 
and re-rated thereafter. The expert panel followed the criteria of Wilson and Jungner 
for each condition: the panelists investigated whether sufficient evidence was present 
to fulfill the criteria for a specific condition and they took their expert opinion about a 




Finally, each indication is classified as ‘appropriate’, ‘uncertain’ or ‘inappropriate’ for the 
procedure under review in accordance with the panelists’ median score and the level of 
disagreement among the panelists. Indications with median scores in the 1-3 range are 
classified inappropriate, those in the 4-6 range as uncertain, and those in the 7-9 range 
as appropriate. However, all indications rated ‘with disagreement’, whatever the median, 
are classified as uncertain. ‘Disagreement’ basically means a lack of consensus, either 
because there is polarization of the group or because judgments are spread over the 
entire 1-9 rating scale. Various alternative definitions for disagreement have been used 
throughout the history of the RAND/UCLA appropriateness method. 
In the present study, a condition was considered to be rated ‘with disagreement’ when 
at least three panelists rated in the 1-3 range, and at least three panelists rated in the 
7-9 range.12
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  60-74 7 8  
  75-84 7 8  
  85+ 6 8  
      
      
       
      60-74 years          75-84 years            85+ years 
Number of ratings: total number of panelists who scored a certain rating. 
Rating scale: rating of appropriateness to screen (1=extremely inappropriate,  
5=uncertain or equivocal, and 9=extremely appropriate). 
 *Median of rating by all panelists (n=11) 
†Personal rating of an individual panelist 
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This study aimed to explore the prognosis of very old people depending on their car-
diovascular disease (CVD) history. This observational prospective cohort study included 
570 participants aged 85 years from the general population with 5-year follow-up for 
morbidity, functional status, and mortality. At baseline, participants were assigned to 
three groups: no CVD history, “minor” CVD (angina pectoris, transient ischemic attack, in-
termittent claudication, and/or heart failure), or “major” CVD (myocardial infarction [MI], 
stroke, and/or arterial surgery). Follow-up data were collected on MI, stroke, functional 
status, and cause-specific mortality. The composite endpoint included cardiovascular 
events (MI or stroke) and cardiovascular mortality. At baseline, 270 (47.4%) participants 
had no CVD history, 128 (22.4%) had minor CVD, and 172 (30.2%) had major CVD. 
Compared to the no CVD history group, the risk of the composite endpoint increased 
from 1.6 (95% confidence interval [CI], 1.1–2.4) for the minor CVD group to 2.7 (95% 
CI, 2.0–3.9) for the major CVD group. Similar trends were observed for cardiovascular 
and all-cause mortality risks. In a direct comparison, the major CVD group had a nearly 
doubled risk of the composite endpoint (hazard ratio, 1.8; 95% CI, 1.2–2.7), compared to 
the minor CVD group. Both minor and major CVD were associated with an accelerated 
decline in cognitive function and accelerated increase of disability score (all p <0.05), al-
beit most pronounced in participants with major CVD. CVD disease status in very old age 
is still of important prognostic value: a history of major CVD (mainly MI or stroke) leads 
to a nearly doubled risk of poor outcome, including cardiovascular events, functional 
decline, and mortality, compared with a history of minor CVD.
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INTRODUCTION
Cardiovascular disease (CVD) is characterized by a high prevalence and incidence up to 
the highest age groups. Moreover, cardiovascular morbidity is an important cause of 
disability and, from middle age onwards, CVD is the leading cause of death.1,2 Therefore, 
prevention of cardiovascular events has high priority and risk prediction models have 
been developed.
In daily practice, populations are usually dichotomized into people with known athero-
thrombotic CVD, such as coronary heart disease, stroke/transient ischemic attack (TIA), 
and peripheral arterial disease, and people without those manifest conditions, but pos-
sibly with risk factors for CVD, such as hypertension, hypercholesterolemia, diabetes, or 
smoking.3-6 Persons without manifest CVD theoretically qualify for the so-called primary 
prevention, be it on a population scale or on a more personal level when their calculated 
CVD risk exceeds predefined thresholds.5,7 Persons with prior CVD are known to have a 
high risk of recurrent CVD8-11 and should, therefore, receive optimal “secondary preven-
tion”, including lifestyle advice and preventive medication. Despite evidence of its value 
also in old age, elderly people do not receive optimal preventive treatment even after 
major events.12-14 At very old age, drug interactions, intoxications, and adverse effects 
can have serious impact on the quality of life.15 Therefore, further risk differentiation 
within those with prior CVD might help clinicians to select those at the highest risk of 
recurrent events. In younger age groups, it is already known that patients with prior 
CVD are at the highest risk of a recurrent cardiovascular event.8 Within patients with 
prior CVD, a recent study showed that a history of ischemic events leads to a greater 
risk of future events than a history of stable coronary, cerebrovascular, or peripheral 
artery disease.16 At present, it is unknown whether these findings can also be applied to 
patients aged 85 and over.
We hypothesized that subgroups with different risks of recurrent CVD might also be 
observed within the population of the oldest old. A history of myocardial infarction (MI) 
or stroke might have a different prognosis than a history of relatively “minor” CVD such 
as stable angina or claudication, TIA, or milder cases of heart failure. This may have clini-
cal consequences for the format and intensity of secondary prevention in these groups 
of older people.
We investigated whether differences in prognosis exist between very old people with 
various levels of prevalent CVD, compared to those with no manifest CVD. Since in 
older populations the outcomes “morbidity” and “functional status” become even more 
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important than mortality, we studied the prognosis not only regarding (cause-specific) 
mortality, but also with respect to recurrent CVD morbidity and functional status.
METHODS
Study population
The Leiden 85-plus Study is a prospective population-based study in 85-year-old inhab-
itants of the city of Leiden, The Netherlands. The study design and characteristics of the 
cohort have previously been described in detail.17,18 In brief, between September 1997 
and September 1999, 705 people from the 1912–1914 birth cohorts living in the city of 
Leiden who reached the age of 85 years were eligible to participate. No exclusion criteria 
were used. From the 705 people who were eligible at age 85, 92 refused participation 
and 14 died before enrolment. A total of 599 (87%) people gave informed consent and 
were enrolled. At baseline and yearly up to the age of 90 years, participants were visited 
at their place of residence to obtain extensive data on health, functioning, and well-
being. In addition, a medical history was obtained from the participant’s primary care 
physician. For all participants, classic cardiovascular risk factors were determined. The 
Medical Ethics Committee of the Leiden University Medical Centre approved the study.
Prevalence of CVD at age 85 years
For each participant, the primary care physician was interviewed about the history of 
CVD using a standardized questionnaire, which included questions on present and 
past cardiovascular pathologies, including MI, stroke, surgery for arterial disease (aorta, 
carotid, coronary, or peripheral arteries), angina pectoris, TIA, intermittent claudication, 
and heart failure. An ECG was recorded. The presence of MI on the ECG was defined as 
the presence of Minnesota Code 1-1 or 1-2 (excluding 1-2-8). Participants were assigned 
to three different groups according to their CVD status: a group with no known history 
of CVD (reference group), a group with a history of “minor” CVD, and a group with a 
history of “major” CVD. Minor CVD was considered present if the primary care physician 
had recorded a history of angina pectoris, TIA, intermittent claudication, and/or heart 
failure. Major CVD was defined as a history of MI (including MI on baseline ECG), stroke, 
or surgery for arterial disease (aorta, carotid, coronary, or peripheral arteries). These 
criteria for minor and major CVD were based on literature in younger age groups.14,19
Clinical endpoints
(Non)fatal myocardial infarction
Up to 90 years of age, all incident fatal and nonfatal MIs were annually registered using 
data from the primary care physician, ECGs, and death registration forms. Incident MI 
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on the ECG was defined as the appearance of Minnesota Code 1-1 or 1-2 or Minnesota 
Code 1-3 in combination with the first appearance of Minnesota Code 5-x in the same 
myocardial area.20 A fatal incident MI was categorized by cause of death codes I21–I23 
(International Classification of Diseases [ICD]-10).
(Non)fatal stroke
Information on incident stroke was collected annually from the primary care physician 
up to 90 years of age. A fatal incident stroke was categorized by cause of death codes 
I61–I69 (ICD-10).
Incident cardiovascular events or cardiovascular mortality
The composite endpoint “incident cardiovascular events or cardiovascular mortality” 
was defined as fatal and nonfatal MI, fatal and nonfatal stroke, or other cardiovascular 
mortality.
Mortality
All participants were followed up for mortality until the age of 95  years. Dates and 
causes of death were obtained from civic and national registries. Causes of death were 
divided into cardiovascular causes (ICD-10 codes I00–I99) and noncardiovascular causes 
(all other ICD-10 codes). Assignment of cause of death was done blinded for baseline 
and follow-up study data.
Functional status
Up to 90 years of age, participants were annually visited by a research nurse at their 
place of residence. Cognitive function was assessed by the Mini-Mental State Examina-
tion (MMSE) with scores ranging from 0 to 30 points (optimal).21 Disability was assessed 
using the Activities of Daily Living (ADL) items from the Groningen Activity Restriction 
Scale with scores ranging from 9 (optimal) to 36 points.22 In those with MMSE scores 
above 18, Cantril’s Ladder of Life with a score from 1 to 10 (optimal) points was used 
as a measure of general well-being23 and the 15-item Geriatric Depression Scale (GDS) 
with scores ranging from 0 (optimal) to 15 points was used to screen for depressive 
symptoms.24
Statistical analysis
Differences in baseline characteristics between the groups according to CVD status were 
analyzed with the chi-square test for categorical variables and the Jonckheere-Terpstra 
test for continuous variables. Time-to-event curves were constructed with the Kaplan–
Meier method and compared using a log-rank test. If no exact time to event was available, 
the time to event was calculated as halfway that particular year. Mortality and morbidity 
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hazard ratios (HR) and corresponding 95% confidence intervals (CIs) were calculated in 
a Cox proportional hazards model adjusted for sex. The same HRs were calculated in a 
model with additional adjustments for the use of antihypertensive medication, income, 
and level of education. Incidence rate was calculated using the timetable method as 
number of incidents per 1,000 person-years at risk with corresponding 95% CIs. Dif-
ferences in cognitive function (MMSE), changes in disability (ADL), general well-being 
(Cantril), and depressive symptoms (GDS) were estimated using linear mixed models 
adjusted for sex and are presented as (predicted) means with standard errors. As a first 
sensitivity analysis, the stratification in groups according to CVD status was repeated at 
the age of 90 years, with updated information about incidence of cardiovascular events 
from 85 to 90 years of age. A second sensitivity analysis was done with risk groups ac-
cording to site of CVD: a group with a history of cardiac CVD (angina pectoris and/or 
MI), a group with a history of cerebrovascular CVD (TIA and/or stroke), a group with 
a history of peripheral CVD (intermittent claudication and/or surgery for noncoronary 
arterial disease), and a group with a history of CVD at multiple sites. Data analysis was 
performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics
For 570 of the 599 participants, all baseline measurements were available. At 85 years 
of age, 270 (47.4%) participants had no history of CVD, 128 (22.4%) participants had 
minor CVD, and 172 (30.2%) participants had major CVD (Table 1). Participants with 
major CVD were more often men (47 versus 27% for minor CVD and 28% for no CVD, 
ptrend <0.001) and more often institutionalized (23 versus 18% for minor CVD and 15% for 
no CVD, ptrend=0.048). They had higher scores of disability (ptrend=0.009) and their MMSE 
scores were the lowest (ptrend <0.001). Only 36% of the participants with minor CVD and 
51% of the participants with major CVD used aspirin or oral anticoagulants. Median 
systolic blood pressure was 154  mmHg (interquartile range [IQR], 143–166), median 
total cholesterol was 5.7 mmol/L (IQR, 4.9–6.4). Participants with major CVD had lower 
HDL cholesterol levels (ptrend <0.001). Use of statins was minimal: no more than 1% of all 
participants used lipid-lowering drugs. From all participants with heart failure (n=74), 
more than half (n=38 [51%]) also had a history of major CVD.
At 90 years of age, 303 (53%) participants were still alive. Follow-up for mortality was 
complete, and for 296 participants, we completed all clinical measurements at 90 years.
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Table 1.  Baseline characteristics of participants from the Leiden 85-plus Study (n=570), 
depending on cardiovascular history.











Women 379 (67) 195 (72) 93 (73) 91 (53) <0.001
Net monthly income >750€ 276 (49) 147 (55) 52 (41) 77 (45) 0.058
Post primary school education 197  (35) 104 (39) 41 (32) 52 (31) 0.091
Noninstitutionalized living 467 (82) 229 (85) 105 (82) 133 (77) 0.048
Functional status
Cognitive function (MMSE) 26 (22-28) 27 (24-29) 26 (23-28) 25 (19-28) <0.001
ADL disability 10 (9-15) 10 (9-13) 10 (9-15) 10 (9-16) 0.009
Subjective well-being (Cantril) b 8 (7-9) 8 (6-9) 8 (7-8) 8 (7-9) 0.177
Depressive symptoms (GDS) b 2 (1-3) 2 (1-3) 2 (1-4) 2 (1-3) 0.636
Cardiovascular characteristics
Classic risk factors
Hypertension c 325 (58) 134 (50) 87 (68) 104 (64) 0.003
RR systolic, mmHg 154 (143-166) 155 (144-166) 154 (142-168) 153 (141-166) 0.332
Hypercholesterolemia d 123 (22) 59 (22) 30 (24) 34 (22) 0.928
Total cholesterol,  mmol/L 5.7 (4.9-6.4) 5.7 (5.0-6.4) 5.8 (4.9-6.4) 5.6 (4.8-6.3) 0.320
HDL cholesterol,  mmol/L 1.3 (1.0-1.6) 1.3 (1.1-1.6) 1.3 (1.0-1.5) 1.1 (0.9-1.4) <0.001
BMI, kg/m² 27 (24-30) 27 (25-30) 27 (24-31) 26 (24-29) 0.096
Diabetes e 89  (16) 38 (14) 19 (15) 32 (20) 0.151
Smoking f 267 (49) 122 (46) 54 (42) 91 (58) 0.029
Medication use
Blood pressure lowering drugs g 316 (57) 111 (42) 92 (72) 113 (71) <0.001
Anticoagulants/aspirin 162 (28) 28 (10) 46 (36) 88 (51) <0.001
Lipid-lowering drugs 6 (1) 1 (0.4) 2 (1.6) 3 (1.7) 0.15
Cardiovascular history
Angina 109 (19) 0 60 (48) 49 (29)
Transient ischemic attack 75 (13) 0 40 (31) 35 (21)
Intermittent claudication 37 (7) 0 12 (10) 25 (15)
Heart failure 74 (13) 0 36 (28) 38 (22)
Myocardial infarction 99 (17) 0 0 99 (58)
Stroke 61 (11) 0 0 61 (36)
 Surgery for arterial disease  h 42 (7) 0 0 42 (25)
Data presented as n (%) for categorical variables, and median (IQR) for continuous variables.
CVD=cardiovascular disease; No CVD=participants with no history of CVD; Minor CVD=participants with a history 
of angina, transient ischemic attack, intermittent claudication or heart failure; Major CVD=participants with a 
history of myocardial infarction, stroke or surgery for arterial disease ; MMSE=Mini-Mental State Examination 
(range 0-30);  ADL=basic activities of daily living (range 9-36); Cantril=Cantril’s ladder of life (range 0-10); 
GDS=Geriatric Depression Scale (range 0-15)
a Chi-square test for categorical variables and Jonckheere-Terpstra for continuous variables; b assessed only in 
participants with MMSE >18; c RR ≥160 systolic at baseline or a history of hypertension; d total cholesterol ≥6.5 
at baseline or statin use; e history of diabetes, antidiabetic medication use or non-fasting glucose ≥11 mmol/L; f 
current or past smoker; g use of ß-blockers, ACE inhibitors, diuretics or calciumchannel blockers as reported by the 




During 5 years of follow-up, 181 (32%) participants reached the composite endpoint, 
including 76 (42%) fatal and nonfatal MI, 76 (42%) fatal and nonfatal strokes, and 29 (16%) 
additional cardiovascular deaths. Figure 1 shows the Kaplan–Meier curves for the three 
groups for the composite endpoint “incident cardiovascular events or cardiovascular 
mortality” (left panel) and all-cause mortality (right panel). Overall, during these 5 years, 
267 (47%) participants died; of which, 106 (40%) died from cardiovascular causes. The 
incidence rate for “incident cardiovascular events or cardiovascular mortality” increased 
from 56 (95% CI, 44–72) per 1,000 person-years at risk in the group with no CVD to 88 
(95% CI, 65–118) in the group with minor CVD and to 164 (95% CI, 144–199) in the group 
with major CVD (Table 2). The risks for a fatal or nonfatal MI, a fatal or nonfatal stroke, and 
the composite endpoint increased from 1.7 (95% CI, 0.9–3.1), 1.7 (95% CI, 0.9–3.2), and 1.6 
(95% CI, 1.1–2.4), respectively, in participants with minor CVD to 2.6 (95% CI, 1.6–4.5), 3.4 
(95% CI, 2.0–5.8), and 2.7 (95% CI, 2.0–3.9), respectively, in those with major CVD. In a direct 
comparison of the group with major CVD with the group with minor CVD, the risk of the 
composite endpoint was nearly doubled in the major CVD group (HR, 1.8; 95% CI, 1.2–2.7).
For cardiovascular mortality, the risks increased from 2.0 (95% CI, 1.1–3.4) in the minor 
CVD group to 3.7 (95% CI, 2.3–5.8) in the major CVD group (ptrend <0.001). For all-cause 
mortality, the risks rose from 1.7 (95% CI, 1.2–2.3) in the minor group to 2.3 (95% CI, 
1.7–3.1) in the major group (ptrend <0.001). After adjustment for the use of antihyperten-
sive medication, income, and level of education, all these estimates remained roughly 
similar (data not shown). When we analyzed the HRs with 10-year follow-up, we found 
similar risks for cardiovascular and all-cause mortality: HR, 1.5 (95% CI, 0.99–2.2) and 1.4 
(95% CI, 1.1–1.8), respectively, for minor CVD and HR, 2.6 (95% CI, 1.9–3.7) and 2.0 (95% 
CI, 1.6–2.5), respectively, for major CVD.
Functional status
At baseline, there were no differences in functional status between participants with 
minor CVD and those with no CVD (Table 3; Fig. 2). But the MMSE score was lower (−2.8 
points, p <0.001) and ADL disability score was higher (2.6 points, p=0.003) in partici-
pants with major CVD. Compared to participants with no CVD, participants with minor 
CVD had an additional annual decrease in MMSE score of −0.19 points (p=0.023) and 
increase in ADL disability score of 0.25 points (p=0.042) over time. Participants with 
major CVD had an additional annual decrease in MMSE score (−0.24 points, p=0.005) 
and increase in ADL disability score (0.61 points, p <0.001). Compared to participants 
with minor CVD, participants with major CVD had an additional annual increase in ADL 
disability score of 0.36 points (p=0.023). All other changes in functional status over time 
were not significant.
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Sensitivity analyses
At 90 years of age, participants were recategorized with the updated clinical information 
from 85 to 90 years of age. Of the participants with complete data at 90 years of age 
(n=296), 119 (40%) had no history of CVD, 93 (31%) had minor CVD, and 84 (28%) had 
major CVD. In participants with minor CVD, the 5-year risk for cardiovascular mortality 
(up to 95 years of age) was not significantly increased (1.1; 95% CI, 0.6–1.9), but partici-
pants with major CVD had a more than twofold increased risk (HR, 2.1; 95% CI, 1.2–3.7). 
For all-cause mortality, the HRs were 1.1 (95% CI, 0.79–1.5) and 2.1 (95% CI, 1.5–3.0), 
respectively.
The second sensitivity analysis was done with different groups according to the site 
of their CVD. There were 25 participants (4.4%) with peripheral CVD, 73 (12.8%) with 
cerebrovascular CVD, 109 (19.1%) with cardiac CVD, and 66 (11.6%) with CVD on more 
than one site (Table 4). HRs were all calculated with the group with no CVD as reference 
group. The HR for fatal or nonfatal stroke was as high as 3.9 (95% CI, 2.2–6.9) for those 
with previous TIA or stroke, and the HR for fatal or nonfatal MI was particularly high (3.4; 
95% CI, 1.9–6.4) in the group with CVD on multiple sites. The HR for cardiovascular mor-
tality was highest in participants with peripheral CVD (3.8; 95% CI, 1.7–8.5). In contrast 
with this high risk of cardiovascular mortality, the HRs for fatal or nonfatal MI and fatal or 
nonfatal stroke in participants with peripheral CVD were low, nearly equal to the group 
with no CVD (1.0; 95% CI, 0.23–4.3 and 1.4; 95% CI, 0.32–5.8, respectively). Except for the 
above-mentioned HRs, the groups did not differ materially.
 
 Figure 1. History of cardiovascular disease (CVD) and 5-year incidence of the composite endpoint 
‘myocardial infarction, stroke and cardiovascular mortality’ (left panel), as well as incidence of all-cause 
mortality (right panel) for three groups with no history of CVD, a history of minor CVD and a history of 
major CVD, respectively. Thick solid line major CVD, thin solid line minor CVDE, dashed line no CVD
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Table 2. Five-year hazard ratios and absolute risks of cardiovascular morbidity and mortality, 








p for trend HR major vs. 
minor 
Morbidity and mortality
Fatal and non-fatal MI 
HR 1 1.7 (0.9-3.1) 2.6 (1.6-4.5) 0.001 1.8 (0.97-3.2)
No. of events 25 (9.3) 17 (13.3) 34 (19.8)
Incidence rate 23 (15-33) 37 (23-58) 65 (47-90)
Fatal and non-fatal stroke 
HR 1 1.7 (0.9-3.2) 3.4 (2.0-5.8) <0.001 2.0 (1.1-3.6)
No. of events 23 (8.5) 16 (12.5) 37 (21.5)
Incidence rate 20 (14-30) 35 (21-56) 69 (51-94)
CV events or CV mortality a
HR 1 1.6 (1.1-2.4) 2.7 (2.0-3.9) <0.001 1.8 (1.2-2.7)
No. of events 61 (22.6) 39 (30.5) 81 (47.1)
incidence rate 56 (44-72) 88 (65-118) 164 (144-199)
Mortality
Cardiovascular
HR 1 2.0 (1.1-3.4) 3.7 (2.3-5.8) <0.001 1.9 (1.2-3.1)
No. of events 29 (10.7) 23 (18.0) 54 (31.4)
Incidence rate 25 (18-36) 48 (32-71) 95 (74-122)
Non cardiovascular
HR 1 1.5 (1.03-2.3) 1.7 (1.2-2.5) 0.001 1.1 (0.7-1.7)
No. of events 66 (24.4) 40 (31.3) 55 (32.0)
Incidence rate 57 (54-72) 83 (62-111) 97 (75-124)
All-cause
HR  1 1.7 (1.2-2.3) 2.3 (1.7-3.1) <0.001 1.4 (1.02-1.9)
No. of events 95 (35.2) 63 (49.2) 109 (63.4)
Incidence rate 82 (68-100) 131 (104-164) 193 (162-227)
Data presented as hazard ratios (HR) with corresponding 95% confidence intervals, absolute 
numbers of events (%), and incidence rates as number of incidents per 1000 person years at risk with 
corresponding 95% confidence intervals.  CVD=cardiovascular disease; No CVD=participants with no 
history of cardiovascular disease (CVD); Minor CVD=participants with a history of angina, transient 
ischemic attack, intermittent claudication or heart failure; Major CVD=participants with a history of 
myocardial infarction, stroke or surgery for arterial disease (aorta, carotid, coronary, or peripheral 
arteries) a composite endpoint: fatal and non-fatal myocardial infarction, fatal and non-fatal stroke and 
cardiovascular mortality





































































































































































































































































































































































































































































































































In this cohort of oldest old from the general population, participants with a history of 
major CVD had a markedly increased risk of recurrent MI, stroke, and functional decline, 
as well as cardiovascular and all-cause mortality. Patients with a history of minor CVD 
had a relatively better prognosis: in nonagenarians, a history of minor CVD was not as-
sociated with mortality anymore. This implies that, within the group of very old patients 
who are eligible for secondary prevention, different risk groups can now be identified 
on the basis of clinical information only. Since the prevention of morbidity and subse-
quent loss of independency is increasingly important in the aging Western societies, 
cardiovascular prevention remains essential up to the highest age groups. Our findings 
underscore the importance of adequate secondary preventive measures in those with 
a history of major cardiovascular events, since these measures have been shown to be 
effective up to high ages.25-33 On the other hand, our results suggest that the potential 
yield of secondary preventive measures in the oldest old might be less in older persons 
with a history of minor CVD.
Our study is the first to analyze prognosis based on a history of “minor” and “major” 
CVD in the general population of the oldest old. This distinction between minor and 
major CVD is based on the difference in risk of cardiovascular events and mortality after 
angina or TIA compared with the risk after an MI or stroke, which has been described 
in younger patients.19,34,35 Our study now also showed a significant difference in cardio-
Table 4. Five-year hazard ratios for cardiovascular morbidity and mortality for participants, 













Fatal and nonfatal MI 1 2.0 (1.1-3.7) 1.9 (0.96-3.9) 1.0 (0.23-4.3) 3.4 (1.9-6.4)
Fatal and nonfatal stroke 1 2.3 (1.3-4.2) 3.9 (2.2-6.9) 1.4 (0.32-5.8) 1.6 (0.68-3.7)
CV events or CV mortality a 1 2.0 (1.4-3.0) 2.3 (1.5-3.5) 1.9 (0.93-3.8) 2.5 (1.6-3.9)
Mortality
Cardiovascular 1 2.8 (1.7-4.6) 3.0 (1.7-5.3) 3.8 (1.7-8.5) 3.1 (1.7-5.5)
Noncardiovascular 1 1.4 (0.90-2.1) 1.5 (0.95-2.4) 1.6 (0.76-3.3) 1.6 (1.0-2.6)
All-cause 1 1.8 (1.3-2.5) 2.0 (1.4-2.8) 2.2  (1.3-3.8) 2.0  (1.4-3.0)
Data presented as hazard ratios (HR) with corresponding 95% CIs
CVD cardiovascular disease, Cardiac angina or MI; Cerebrovascular TIA or stroke; Peripheral claudication 
or operation for non-coronary arterial disease; Multiple sites CVD on more than one of cardiac, 
cerebrovascular or peripheral sites
a Composite endpoint: fatal and nonfatal MI, fatal and nonfatal stroke and cardiovascular mortality
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vascular morbidity and mortality between groups with a history of minor and major 
CVD in participants aged 85 years and over. Most other studies, performed in younger 
age groups, have evaluated risks after an event in a specific cardiovascular bed (cardiac, 
cerebral, or peripheral)34,36-38 or observed differences in risk between one or multiple 
CVD sites.10,36,37,39 The high risk of recurrent stroke in the group with a history of TIA or 
stroke that we observed is in line with previous studies.10,34,39,40
In keeping with earlier reports, in the present study, the risk of cardiovascular mortality 
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Figure 2. Changes in cognitive function, disability, subjective well-being, and depressive symptoms 
over time as estimated from linear mixed models adjusted for sex. Data are presented as the means with 




cular morbidity risk in this group was relatively low.10,34,39,40 In contrast with younger age 
groups, mortality risks in our study were not higher in participants with multiple-site 
CVD.10,36,37,39 In very old age, it seems that major CVD, rather than multiple CVD, is of 
prognostic value.
Previous studies have revealed a significant decline in physical functioning after stroke 
and MI in 70-year-olds41,42 and a negative impact on neurocognitive function.42-44 Our 
study confirmed these data in the very old.
Our study has several strengths. First, our results can be easily applied in day to day medi-
cal practice. The current electronic medical records provide clinicians a rapid overview 
of the cardiovascular history without any extra costs or effort. Secondly, our population-
based study had a high participation rate (87%) and no exclusion criteria, both allowing 
our conclusions to be generalized to the oldest old in the general population. Finally, we 
studied multiple relevant outcomes for an ageing population: mortality, morbidity, and 
functional status. A limitation might be that CVD history was based on the diagnosis of 
the primary care physicians, using variable diagnostic standards. However, this reflects 
clinical reality in primary care and previous research has shown the accuracy of data 
recorded in general practice to be very high.45 In view of the fact that this study was 
the first to discriminate major and minor CVD in very old age, we recommend that this 
analysis be repeated in another cohort.
Evidence that medication for secondary cardiovascular prevention is recommendable 
up to the highest age groups is increasing.25-33,46 In this cohort, the use of secondary 
preventive medication was far from optimal, leaving room for improvement. From our 
results, it can be derived that distinct groups are discernible within those who should 
receive secondary prevention. This is an important finding, since at very old age, 
polypharmacy,15,47 treatment adherence,13 and the delicate balance between benefit 
and harm13,47,48 raise a challenge for clinicians in day to day practice.49,50 The results of 
our study may help them to make appropriate treatment decisions, taking all relevant 
prognostic information into account.
In conclusion, in very old age, the CVD history is an easy tool for clinicians to identify pa-
tients who are at high risk for new cardiovascular events, functional decline, and cardio-
vascular mortality, as well as all-cause mortality. A history of major CVD nearly doubles 
the risk of a recurrent cardiovascular event or cardiovascular mortality compared with a 
history of minor CVD. Our results encourage both physicians and 85-year-olds with a his-
tory of major CVD to maximize their cardiovascular preventive efforts. However, when 
adverse effects or harmful interactions arise in a very old patient with minor CVD, the 
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balance between benefit and harm could change and strict continuation of preventive 
medication might be reconsidered.
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To assess the effect of preventive pravastatin treatment on coronary heart disease (CHD) 
morbidity and mortality in older persons at risk for cardiovascular disease, stratified for 
plasma levels of homocysteine.
Design
A post-hoc subanalysis in the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER), started 1997, which is a double-blinded randomized placebo-controlled trial 
with a mean follow-up of 3.2 years.
Setting
Primary care setting in two of the three PROSPER study sites (Netherlands and Scotland).
Participants
Individuals (n=3522, aged 70-82 years, 1765 men) with a history of or risk factors for car-
diovascular disease, were ranked in three groups depending on baseline homocysteine, 
sex and study site.
Intervention 
40 mg pravastatin versus placebo.
Measurements
Fatal and nonfatal CHD and mortality. 
Results 
In the placebo group, participants with high homocysteine (n=588) had a 1.8 higher 
risk (95% CI 1.2–2.5, p=0.001) of fatal and nonfatal CHD compared to low homocysteine 
(n=597). The absolute risk reduction in fatal and nonfatal CHD with pravastatin treatment 
was 1.6% (95% CI -1.6–4.7) in the low homocysteine group vs. 6.7% (95% CI 2.7–10.7) in 
the high homocysteine group (difference 5.2%, 95% CI 0.11–10.3, p=0.046). Therefore, 
the number needed to treat (NNT) with pravastatin for 3.2 years for benefit related to 
fatal and nonfatal CHD events was 14.8 (95% CI 9.3–36.6) for high homocysteine com-
pared to 64.5 (95% CI 21.4–∞) for low homocysteine. 
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Conclusion
In older persons at risk for cardiovascular disease, those with high homocysteine are at 
highest risk for fatal and nonfatal CHD. With pravastatin treatment, this group has the 




The aim of cardiovascular risk management is to reduce the incidence of cardiovascular 
events in a high-risk population. To select those with high cardiovascular risk, clinical car-
diovascular risk scores, such as the Framingham Risk Score1 and the Systematic Coronary 
Risk Evaluation (SCORE)2, are used worldwide. However, their accuracy to predict risk on 
cardiovascular outcomes declines with advancing age.3-6 Because the prevalence and 
incidence of cardiovascular disease increases exponentially with age,7-9 it is suggested 
to offer preventive treatment to everyone over a specified age without measuring other 
risk factors.10 Others, however, emphasize the need for risk stratification in old age.11;12 
Recently, the Leiden 85-plus Study (and others) showed that homocysteine is predictive 
of cardiovascular events in old age.13-18 
Since, according to Wilson and Jungner, risk predictors are only clinically meaningful 
when effective preventive treatment is available,19 we need to establish which treatment 
possibilities exist (and are appropriate) for older persons with high homocysteine to 
lower their cardiovascular risk. Large randomized controlled trials (RCTs) and meta-
analyses show that lowering plasma homocysteine by treatment with folate has no 
beneficial effect on the incidence of cardiovascular events.16;20;21 The PROspective Study 
of Pravastatin in the Elderly at Risk (PROSPER)22 has shown that pravastatin lowers the 
risk of coronary heart disease (CHD) in older people in general, but not the risk for fatal 
or non-fatal strokes. We questioned whether older persons with high homocysteine 
levels would benefit more from this conventional preventive treatment, also compared 
to those with lower levels. Therefore, we performed a post-hoc subanalysis in PROSPER 
(a large double-blinded randomized placebo-controlled trial) to assess the effect of 




The protocol of PROSPER has been published elsewhere.23 Briefly, in 1997-1999 a total 
of 5804 individuals were enrolled in Scotland (n=2520), Ireland (n=2184) and the Neth-
erlands (n=1100). Men and women aged 70-82 years were recruited, with either pre-
existing vascular disease (coronary, cerebral, or peripheral) or an increased risk of such 
disease because of smoking, hypertension or diabetes. Their plasma total cholesterol 
was required to be 154-347 mg/dl (4.0-9.0 mmol/L) and their triglyceride concentrations 
≤531 mg/dl (≤6.0 mmol/L). Individuals with congestive heart failure (New York Heart 
Homocysteine as predictor of pravastatin treatment effect
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Association functional class III and IV) or poor cognitive function (Mini-Mental State 
Examination (MMSE) score <24 points) were excluded. Participants were randomized 
either to a group receiving 40 mg pravastatin a day or to a control group receiving a 
placebo, and were followed (on average) for 3.2 years. Throughout the study, all study 
personnel was unaware of the allocated study medication status of the patients. The in-
stitutional ethics review boards of all centers approved the protocol, and all participants 
gave written informed consent. 
Determination of homocysteine
After blood drawing, blood samples were kept at room temperature until they were pro-
cessed in the laboratory to be stored in the biobank (-80oC). In 2010 homocysteine con-
centrations were measured in the biobank EDTA plasma samples, from samples taken at 
baseline (blood samples n=5757, missing n=47) and again at six months. Measurements 
were done in batches after reduction to the free form with a fluorescence polarization 
immunoassay on an IMx analyzer (Abbott, Abbott Park, IL, USA). 
The median plasma level of homocysteine in The Netherlands (n=1100) was 14.1 µmol/L 
(IQR 11.8 -17.0), in Scotland (n=2505) 17.9 µmol/L (IQR 15.3-21.8), and in Ireland (n=2152) 
18.8 µmol/L (IQR 15.6-23.3). However, there were differences in standard operating 
procedures per study site, i.e. the Dutch and Scottish blood samples were processed 
within eight hours, whereas in Ireland this processing frequently exceeded eight hours. 
Statistical analysis showed that the variance in log homocysteine for Scotland and the 
Netherlands was comparable (F=2.4, p=0.120), but both showed a significant differ-
ence in variance compared with Ireland  (Scotland vs. Ireland F=5.4, p=0.020 and the 
Netherlands vs. Ireland F=11.2, p=0.001). Since plasma homocysteine levels increase by 
0.5-1.0 µmol/L per hour in blood at room temperature,24-26 differences in lag time could 
explain the differences in variance between Ireland and the other countries. Therefore, 
we decided to exclude participants from Ireland from this analysis. 
Outcomes
The outcomes, described in the design of PROSPER,23 were the incidence of fatal and 
nonfatal CHD (including definite or suspected CHD mortality and non-fatal myocardial 
infarction), non-fatal myocardial infarction (MI), CHD mortality, non-CHD mortality, and 
all-cause mortality. All CHD endpoints were assessed by the PROSPER Endpoints Com-
mittee, which was blinded for study medication and for plasma levels of homocysteine.
Data analysis
At baseline, participants were ranked in three equal groups (low, medium and high ho-
mocysteine) based on plasma homocysteine level, sex and study site. Per homocysteine 
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group, characteristics between placebo and treatment were compared using indepen-
dent t-tests for continuous data and Pearson Chi-square tests (df=1) for categorical data.
Predictive value of homocysteine in the placebo group
The cumulative incidence rates of fatal and nonfatal CHD and all-cause mortality for the 
three homocysteine groups are presented in Kaplan-Meier curves and compared with 
the log rank test (df=2). Hazard ratios (HRs) and corresponding 95% confidence intervals 
(95% CI) for sex- and study site-specific tertiles of homocysteine were calculated for 
the endpoints using Cox proportional hazard models (reference low homocysteine), 
with adjustment for age. To further investigate the independent predictive value of 
homocysteine, we additionally adjusted for baseline history of cardiovascular disease, 
for baseline Framingham risk factors [smoking, diabetes, left ventricle hypertrophy, 
systolic blood pressure, total cholesterol, high density lipoprotein (HDL)] and for earlier 
published predictors in PROSPER [CRP, HDL and creatinine clearance (Cockcroft-Gault)].
Treatment effect comparing placebo and treatment group
The treatment effects of pravastatin vs. placebo per homocysteine group were calcu-
lated with two methods. First, per homocysteine group, the cumulative incidence rate 
for fatal and nonfatal CHD and all-cause mortality are presented for those on placebo 
and those on pravastatin with Kaplan-Meier curves and compared with the log rank test 
(df=1) and with Cox proportional hazard models. No adjustments were made. The pres-
ence of multiplicative interaction was formally tested by adding the interaction term 
(treatment x homocysteine group) to the Cox regression model. All analyses were on an 
intention-to-treat basis.  
Second, the absolute risk reduction by treatment with pravastatin was calculated. Dif-
ferences in absolute risk reductions between the homocysteine groups were tested 
with a z-test. Numbers needed to treat (NNT) to benefit were calculated over the mean 
follow-up of the trial (3.2 years) based on the difference in cumulative proportion of 
surviving in the placebo and pravastatin group.27;28 Because creatinine clearance seems 
to be associated with the level of homocysteine, we carried out a subgroup analysis for 
absolute risk reduction for fatal and nonfatal CHD and for all-cause mortality in people 
with creatinine clearance ≥30 ml/min.
Influence of treatment with pravastatin on homocysteine
To investigate whether pravastatin treatment influences the plasma levels of homo-
cysteine, we measured homocysteine concentrations after six months treatment for 
1832 participants (183 on placebo and 1649 on pravastatin). The effect of treatment of 
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pravastatin on plasma levels of homocysteine was tested after six months with linear 
regression analysis, adjusted for baseline homocysteine. 
RESULTS
In total, 3620 PROSPER participants from the study sites in The Netherlands and Scotland 
were eligible for this study. Since 15 participants had missing biobank samples and 83 
had missing homocysteine measurements, 3522 participants (1764 placebo and 1758 
pravastatin) were included in the analyses. The cut-off values of the homocysteine ter-
tiles (33% and 67%) in the Netherlands (n=1049) were 11.7 and 14.7 µmol/L, respectively, 
for women, and 13.5 and 16.9 µmol/L, respectively, for men; for Scotland (n=2473) these 
limits were 15.4 and 19.6 µmol/L, respectively, for women, and 16.9 and 21.0 µmol/L, 
respectively, for men. 
Baseline characteristics
Table 1 presents baseline characteristics of the total group of participants and per ho-
mocysteine group, stratified for placebo or pravastatin. In the total group, mean age of 
the participants was 75 (SD 3.4) years and 48% had a history of cardiovascular disease. 
The mean homocysteine level at baseline was 18.3 (SD 7.1) µmol/L. Per homocysteine 
group, there were no differences in baseline characteristics between the pravastatin and 
placebo groups. Remarkably, the proportion of diabetic patients was lower in the high 
homocysteine group.
Predictive value of homocysteine in the placebo group
Figure 1 shows the cumulative incidence of fatal and nonfatal CHD and all-cause mortal-
ity for the three homocysteine groups within the placebo group. Compared to partici-
pants with low homocysteine, those with medium homocysteine had no increased risk 
of fatal and nonfatal CHD (HR 1.1, 95% CI 0.76–1.6, p=0.569), but those with high homo-
cysteine had a 1.8 fold increased risk (95% CI 1.2–2.5, p=0.001). For overall mortality, the 
HRs were 1.0 (95% CI 0.67–1.5, p=0.992) and 1.7 (95% CI 1.2–2.5, p=0.003), respectively. 
These estimates did not change by additional adjustments for history of cardiovascular 
disease, for Framingham Risk Factors, and for CRP, HDL and creatinine clearance (data 
not shown). 
Similarly, participants with high homocysteine also had an increased risk for non-fatal 
MI, CHD mortality and non-CHD mortality. Furthermore, for all these outcomes no dif-
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Treatment effect depending on homocysteine
Figure 2 presents the cumulative incidence of fatal and nonfatal CHD and all-cause 
mortality in participants with and without pravastatin per homocysteine group. In 
participants with high homocysteine, an HR of 0.57 (95% CI 0.41–0.81, p=0.002) was 
found as treatment effect of pravastatin on fatal and nonfatal CHD, and an HR of 0.70 
(95% CI 0.50–0.98, p=0.036) as treatment effect on all-cause mortality. In medium and 
low homocysteine, there was no significant difference in cumulative incidence between 
placebo and pravastatin treatment. Formal testing of multiplicative statistical interac-
tion was not significant (Figure 2). Similar patterns were seen for non-fatal MI and CHD 
mortality. For non-CHD mortality, we found no effect of treatment with pravastatin in all 
three homocysteine groups (data not shown). 
Table 2 presents absolute treatment effects of pravastatin per homocysteine group. The 
absolute risk reduction in fatal and nonfatal CHD by pravastatin treatment was 1.6% 
(95% CI -1.6–4.7) in the low homocysteine group, and 6.7% (95% CI 2.7–10.7) in the 
high homocysteine group (absolute risk reduction difference 5.2%, 95% CI 0.11–10.3, 
p=0.046). For all-cause mortality the absolute risk reductions were -0.66% (95% CI 
-4.0–2.7) and 4.6% (95% CI 0.78–8.4), respectively (absolute risk reduction difference 
5.2%, 95% CI 0.19-10.3, p=0.042). 
In persons with creatinine clearance ≥30 ml/min (n=3426) we found a mean homocys-
teine value of 18.3 µmol/L and in persons with creatinine clearance <30 ml/min (n=96) 
a mean homocysteine value of 19.0 µmol/L (p=0.292). Because creatinine clearance 
is known to be associated with the level of homocysteine we carried out a subgroup 
Fatal and nonfatal CHD All-cause mortality
Figure 1. Cumulative incidence of fatal and nonfatal CHD and all-cause mortality depending on baseline 
plasma levels of homocysteine in the placebo group (n=1764).  
HR=Hazard ratio (95% CI) high homocysteine group vs. low homocysteine group, adjusted for age.
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analysis in persons with creatinine clearance ≥30 ml/min. The absolute risk reductions by 
pravastatin treatment remained similar (fatal and nonfatal CHD 6.0% (95% CI 0.84–11.1, 
p=0.023) and all-cause mortality 5.8% (95% CI 0.70–11.0, p=0.026)).




Figure 2. Cumulative incidence fatal and nonfatal CHD and all-cause mortality depending on pravastatin 
treatment, stratified for plasma levels of homocysteine at baseline. 
*p for multiplicative interaction = 0.208
†p for multiplicative interaction = 0.097


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































For fatal and nonfatal CHD the NNT with pravastatin to benefit for 3.2 years is 14.8 (95% 
CI 9.3–36.6) in the high homocysteine group, 81.3 (95% CI 21.5–∞) in the medium group, 
and 64.5 ( 95% CI 21.4–∞) in the low homocysteine group (p high vs. low=0.046) (Figure 
3). For all-cause mortality we found a beneficial result in the high homocysteine group 
(NNT 21.8, 95% CI 11.9–129), but no benefit in the medium and low homocysteine 
groups (p high vs. low=0.042). 
Influence of pravastatin on homocysteine
After six months treatment, the difference in homocysteine levels was -0.52 μmol/L (95% 
CI -1.1–0.07) for those on pravastatin compared to baseline (linear regression, p=0.082).
Absolute risk reduction in % 
 ∞ 20 10 6.7 
NNTH NNTB 
20 10 6.7 
5 10 15 -5 -10 -15 0 

























Homocysteine groups Outcomes 
Figure 3. Number needed to treat with pravastatin after 3.2 years dependent on homocysteine level at 
baseline.
NNTH= Number needed to treat to harm
NNTB= Number needed to treat to benefit
CHD=coronary heart disease; MI=myocardial infarction
p-value of difference between high and low homocysteine group for absolute risk reduction in % and for 
number needed to treat estimated by z-test
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DISCUSSION
This study suggests that homocysteine may be a promising new CHD risk predictor in 
older people, since high plasma homocysteine not only selects older persons at high 
risk for fatal and nonfatal CHD and all-cause mortality, but also identifies those with 
the highest absolute risk reduction by pravastatin and lowest NNT to prevent fatal and 
nonfatal CHD. 
Earlier studies showed that older persons with high levels of homocysteine are at in-
creased risk for cardiovascular events and homocysteine level may provide additional risk 
stratification beyond traditional risk factors.13-18 For example, Veeranna et al. examined 
whether adding homocysteine to a model based on traditional cardiovascular disease 
risk factors improved classification. In two younger population cohorts, they found that 
addition of homocysteine level to the Framingham Risk Score significantly improved 
risk prediction.18 Moreover, for persons aged 85+ years, De Ruijter et al. showed that 
the classic risk factors as included in the Framingham Risk Score no longer accurately 
predicted cardiovascular mortality in those with no history of cardiovascular disease, 
while a single measurement of homocysteine did accurately identify those at high 
risk of cardiovascular mortality.13 Our findings not only confirm studies reporting that 
homocysteine predicts CHD risk in old age, but also show the independent predictive 
capacity in a selected population of older persons with increased cardiovascular risk. A 
recent meta-analysis showed that a moderate homocysteine elevation due to genetic 
variance does not meaningfully affect CHD risk.29 This finding indicates that circulat-
ing homocysteine levels within the normal range are not causally related to CHD risk. 
Moreover, large RCTs and their meta-analyses show that lowering plasma homocysteine 
by treatment with folate has no beneficial effect on the incidence of cardiovascular 
events.16;20;21 Therefore, the underlying biological pathway to explain predictive value of 
high homocysteine for cardiovascular diseases, if there is one, to date is still unknown. 
Homocysteine may be seen as an epiphenomenon rather than a causal agent, but this 
does not refute its predictive abilities. 
Since homocysteine showed to be not causally related to cardiovascular disease, it was 
unknown if preventive treatment could be offered to those with high homocysteine 
to reduce their cardiovascular risk. In the AFCAPS/TexCAPS study,30 with only a small 
proportion of old individuals, the beneficial effect of statin treatment in people with 
elevated homocysteine levels was limited to people with an LDL level higher than 149 
mg/dL.  Our results further extend the findings from the AFCAPS/TexCAPS study by 
demonstrating that the benefits of statin treatment may differ by homocysteine levels 
among high-risk patients with an average LDL level of 148 mg/dl. If these findings hold 
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true in a subsequent study, there could be a role for measurement of homocysteine lev-
els to help guide decisions on statin use in older individuals, which is a widely available 
treatment, also for older persons. This is an important criterion of Wilson and Jungner 
underlying screening.19 
The present study revealed other findings that deserve further examination. First, al-
though we only found a clear CHD risk benefit from pravastatin therapy over the trial 
period of 3.2 years in older persons with high homocysteine and not in older persons 
with low and medium homocysteine, we did not find multiplicative interaction for the 
treatment effect. Therefore, there is a possibility that pravastatin has the same treatment 
effect in the three homocysteine groups. However, even when the relative treatment 
effect is similar between these groups, those at highest absolute risk will have most ben-
efit expressed in absolute risk reduction. This absolute risk reduction and corresponding 
NNT is very important in clinical practice and guidelines, since this indicates the number 
of persons who need to be treated in order to prevent one event. 
Second, the effect of pravastatin over the homocysteine groups does not show a linear 
trend. This finding could be explained by a lack of power due to a small number of 
events in the low and medium homocysteine groups, therefore a possibility of random 
variation cannot be excluded. However, it is also possible that pravastatin therapy is only 
effective in people with homocysteine beyond a certain cut-off value. The possibility of 
absolute cut-off values requires more in-depth study, investigated in a population with 
consistent blood sampling and storage procedures.
Third, we found that plasma levels of homocysteine did not change significantly with 
pravastatin treatment during a six-month period, although a small reduction was seen. 
Further examination is needed to determine the effect of pravastatin treatment on 
homocysteine levels. If pravastatin does not affect the homocysteine level, homocys-
teine measurement might be useful to evaluate the need for continuing cardiovascular 
preventive therapy in persons under pravastatin treatment. 
For new biomarkers, others have investigated whether high cardiovascular risk and 
corresponding benefit from treatment could be predicted. A large-scale RCT31 and an 
earlier analysis in PROSPER32 showed that baseline C-reactive protein concentration 
predicts cardiovascular risk, but does not predict the relative CHD risk benefits of pravas-
tatin therapy. Other analyses in PROSPER showed that high-density lipoprotein33 and 
creatinine clearance34 can predict benefit for prevention of fatal and nonfatal CHD by 
pravastatin therapy. However, a high plasma level of homocysteine remained predictive 
for a beneficial effect of pravastatin even in persons with creatinine clearance ≥30 ml/
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min. Furthermore, pravastatin was more effective in preventing cardiovascular events 
in those without diabetes.22 We showed that adjustment for these predictors did not 
influence the predictive value of homocysteine. A next step is to study the clinical value 
of homocysteine and other biomarkers by comparing their predictive value in combina-
tion with treatment response, to develop the most effective predictors of cardiovascular 
risk and treatment benefit. This is particularly important since statins are not without 
side-effects or costs, and targeting those at maximal risk and with most to gain would 
be both clinically and economically advantageous. 
Strength and limitations
This study was embedded in the PROSPER trial, a large double-blinded randomized 
placebo-controlled trial in older persons. This landmark clinical cardiovascular trial 
with older participants was performed following guidelines of good clinical practice, 
including endpoints that were uniformly assessed by the Endpoint Committee. Since 
homocysteine was assessed after closure of the trial, plasma levels of homocysteine had 
no influence on the study procedures, clinical treatment during follow-up, or on the 
decisions of the Endpoint Committee. 
A limitation of this study is that the PROSPER study procedures were not originally 
designed to collect optimal blood samples for the assessment of plasma homocysteine. 
Therefore, it was appropriate to use data from only two of the three PROSPER study 
sites. However, in these two sites, it is still possible that some samples were stored at 
room temperature until maximally eight hours before processing. Since this could lead 
to misclassification, that was assumed to be non-differential, this could have resulted in 
underestimation of the differences in treatment effect by homocysteine levels. Because 
it is also known that homocysteine levels vary between countries,13;35;36 more studies 
are needed to validate the absolute cut-off values of homocysteine to select elderly at 
highest risk in clinical practice. Moreover, data about the use of B vitamins, that lower 
the levels of homocysteine, are not available. Another limitation of this study is that 
the treatment-by-homocysteine group multiplicative interaction was not significant, 
although the absolute risk reduction by high versus low homocysteine was significant 
(p=0.046 for fatal and nonfatal CHD and p=0.042 for all-cause mortality). The possibility 
of a type 1 error from multiple comparisons cannot be excluded. It might also be seen 
as a limitation that these analyses focused only on the value of homocysteine to predict 
the CHD risk and treatment effect, rather than investigating the etiological mechanisms 
behind our findings. Predictive and etiological studies will contribute to the further 




A recent analysis on cost-effectiveness of statin treatment in primary care showed that 
even in high age groups it is useful to stratify for risk of cardiovascular outcomes.12 Our 
study shows that homocysteine may usefully predict CHD risk in the PROSPER popula-
tion of old persons with increased cardiovascular risks. As a consequence, individuals 
without traditional risk factors and, thus, with the lowest risks were excluded. Before 
these results can be implemented in current guidelines, further research is needed to 
find a cutoff value of homocysteine and confirm that high-risk older adults with high 
homocysteine levels get more benefit from pravastatin treatment. Moreover, whether 
homocysteine is useful in predicting benefits from pravastatin treatment for low-risk or 
intermediate-risk older adults remains to be investigated.
In conclusion, homocysteine is a promising CHD risk predictor in old age, not only 
because high plasma homocysteine identifies older persons at high risk for fatal and 
nonfatal CHD, but also because those persons have the highest absolute risk reduction 
by pravastatin treatment and lowest number needed to treat to prevent fatal and non-
fatal CHD. This is an important step in the further development of CHD risk stratification 
and treatment for older people. 
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Preventive care traditionally refers to measures taken to prevent disease and injury 
and, generally, not to less well-defined goals such as maintenance of independence 
and wellbeing. With old age, however, the prevalence of ailments and chronic diseases 
increases, leading to a decrease in independence and wellbeing. Because older people 
differ considerably from each other with regard to health and functional status, a ‘one 
size fits all’ program for prevention is not possible. For some subgroups, preventive care 
might be used to enable people to live as independently as possible by preventing or 
postponing disability and social isolation. For others, prevention of disease to lengthen 
life expectancy will probably be the most suitable aim. Moreover, preventive programs 
can be organized collectively as well as individually. These two dimensions of preven-
tive care for older people are described in Chapter 1. In short, it remains unclear which 
approach and which aim will be most appropriate in preventive care for older people. 
However, it is possible that specific subgroups of older people can be identified who will 
need the same approaches for the same aims. This chapter discusses the possibilities 
to develop strategies (varying in their aim and approach) in preventive care for older 
people and makes some recommendations for clinical practice and future research. 
1. Exploration of aims in preventive care for older people
Is there scientific support for the idea that the aim of prevention is not only to prevent disease 
and injury, but also to maintain independence and wellbeing?
In current health policy 1-4 much attention is directed to the older population. The aging 
society implies that more people will be dependent on caregivers and healthcare facili-
ties. Health care for older persons might contribute to the maintenance of good physical 
and mental health, and might help older people to stay independent and participate in 
social activities for a longer period of time. It is important to develop strategies in health 
care for older people which not only contribute to their life expectancy but also help to 
maintain their daily functioning and wellbeing. Therefore, it is necessary to investigate 
whether preventive strategies can indeed contribute to these aims.
Chapter 2 shows that general practitioners (GPs) believe that preventive care can con-
tribute to life expectancy and to functioning in daily life and wellbeing. According to 
GPs, the focus of preventive care for their older patients depends on the level of vitality 
of the individual person, rather than on their age. In all discussions, the level of vital-
ity as perceived by the GP tends to influence their ideas about preventive care. When 
older people become less vital and thus more vulnerable, the scope of preventive care 
supplied by the GP shifts from a ‘disease model’ to a ‘functional model’, and from mainly 
cardiovascular risk management to preventing functional decline. These findings reveal 
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that GPs believe that vulnerable older people require a prevention strategy that differs 
from that for vital older people; however, it is not known to what extent this idea actually 
mirrors the behavior of GPs. Current international screening guidelines5-13 tend to ignore 
a differentiation in aims that depend mainly on patient characteristics. Therefore, it is 
also unknown whether screening can contribute to the prevention of functional decline 
in older people. 
In Chapter 5 evidence for the contribution of screening to the prevention of functional 
decline in older persons was investigated and the outcomes were stratified for three 
age groups (60-74, 75-84 and 85-plus years) and three levels of vitality, i.e. for the gen-
eral population, and for the population divided into vital and vulnerable persons. The 
appropriateness of screening was assessed by an expert panel using the RAND/UCLA 
method. In general, the panelists appreciated the idea to investigate the contribution 
of screening to the maintenance of independence and wellbeing, whereas until then 
screening was mainly applied to the prevention of disease. The panelists considered 
vulnerability to be an important factor in the determination of the appropriateness of 
screening to maintain independence and wellbeing, whereas age scarcely influenced 
the appropriateness of screening. Although, according to current knowledge, evidence 
for the value of screening vulnerable people is still lacking, the panelists expect benefits 
for (in particular) vulnerable people when more tests and interventions are developed 
for this specific group. This conclusion is in accordance with the ideas presented by the 
GPs (Chapter 2).
In conclusion, many health policies aim at the maintenance of independence and 
wellbeing for older people. GPs and other professionals in geriatric care also consider 
this aim to be relevant for prevention, but the appropriateness of this aim appears to 
depend on the level of vitality of the individual older person. Therefore, maintenance 
of independence and wellbeing is an important aim in preventive care, complementing 
the traditional aim of prevention of disease. Especially in older vulnerable individuals, 
professionals expect that preventive care can contribute to the maintenance of inde-
pendence and wellbeing. 
2. Maintenance of independence and wellbeing
a. Is it possible to identify older people who will benefit from a preventive approach which 
contributes to the maintenance of independence and wellbeing?
To develop preventive strategies to maintain independence and wellbeing, screening 
instruments are needed to identify vulnerable older people at high risk for deteriora-
tion in the near future. It is known that chronic diseases 14-20 and multimorbidity19-21 
are strongly related to disability. Moreover, although a variety of tools are available to 
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measure vulnerability in various ways,22-28 there is no standardized and valid method to 
screen for manifestations of vulnerability. 
In the discussions in the focus group study, the GPs appeared to be able to differentiate 
between vulnerable and vital older persons (Chapter 2), even though no definitions for 
‘vital’ and ‘vulnerable’ were specified. Interestingly, during the discussions there was no 
confusion between the GPs regarding these two categories of older persons; it seems 
that the GPs used an implicit concept of vulnerability. Perhaps GPs share a unique per-
spective as to what defines vulnerability; on the other hand, perhaps they remained un-
aware of actual distinctive perspectives related to the concept ‘vulnerability’. Therefore, 
the variability between GPs in their assessment of vulnerability was studied in Chapter 4. 
In the RAND study (Chapter 5), the expert panel started their discussion by formulating 
a definition of vulnerable persons, i.e. older people with (simultaneously) a high preva-
lence of diseases/disorders, a poorer prognosis, disability of various kinds, and multiple 
problems. These general characteristics appeared to be sufficient for the expert panel to 
discuss and assess the appropriateness of the screening topics. 
Due to the lack of a gold standard for the selection of vulnerable older people at risk 
for functional decline, we investigated two ways to predict the vulnerability of older 
persons. In the first study (Chapter 3) the predictive value of multimorbidity was ex-
plored for its association with an increase in disability over time and the role of cognitive 
impairment in this association. The Leiden 85-plus Study, a population-based study of 
individuals aged 85-plus (Chapter 3) with a 5-year follow-up, showed that the predic-
tive value of multimorbidity for an increase of disability in activities in daily living (ADL) 
varies with cognitive function in very old people. Remarkably, multimorbidity predicted 
an accelerated increase of disability in ADL only in older people with a Mini-Mental 
State Examination (MMSE) score ≥28 points at baseline. In persons with a lower MMSE 
score this predictive relation was not present, possibly because the cognitive problems 
dominated the functionality. This implies that the prevalence of multimorbidity in older 
people (a relatively easy measurement for GPs) is an indicator for risk in deterioration of 
ADL performance in only 35% of this age group, because 65% of the 85-plus population 
no longer has an MMSE score ≥28 points. Therefore, preventive programs to promote 
older people to live as independently as possible cannot be based on multimorbidity as 
the sole selection criterion. At least a two-stage screening test is needed, which encom-
passes cognition screening as a first step and multimorbidity screening as the second, in 
order to select older people at increased risk for disability. 
Since the effect of cognitive impairment seems to dominate the effect of multimorbid-
ity on ADL performance, in clinical practice the cognitive function of older people is 
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probably a better predictor of increased disability in ADL than multimorbidity. To select 
people with cognitive impairment using the MMSE measurement is a relatively complex 
strategy, partly because MMSE measurement is labor-intensive and also costly. It is ques-
tionable whether a formal MMSE measurement is needed to select people with optimal 
cognitive function. Most likely GPs know their patients well enough to classify them by 
‘gut feeling’ into those with and without optimal cognitive function. In this way they 
can limit testing to those for whom there is some doubt about their level of cognitive 
functioning.
GPs seem to apply an intuitive gut feeling in various clinical situations. Stolper et al.29 
reported that a gut feeling can produce a ‘sense of alarm’; this is defined as an uneasy 
feeling perceived by GPs when they become concerned about a possible adverse out-
come, even when a specific indication is lacking. ‘There’s something wrong here’ seems to 
be the sense of alarm that activates the diagnostic process of GPs and motivates them 
to initiate specific management to prevent serious health problems. A prerequisite for 
this gut feeling is sufficient knowledge of the person and, for several issues, this requires 
long-term observation (to establish a decline/irregularity). This stresses the need for 
regular consultation with or visits to older patients. 
Similarly, the notion of ‘vulnerability’ may also be a concept such as gut feeling. GPs 
seemed to share a unique perspective as to what constitutes vulnerability (Chapter 2), 
without a need for explicit criteria or a gold standard. Chapter 4 examines variability in 
the assessment of vulnerability between GPs to determine whether GPs indeed share a 
uniform concept of vulnerability. The percentage of patients aged 75-plus assessed as 
being vulnerable by the GP varied per GP: median 32.0% (IQR 19.5 to 40.1%, range 2.4 
to 81.0%). This variation was not only due to differences in the case mix of their patients, 
but also to differences in the weighing that GPs attribute to some patient characteristics 
in the assessment of vulnerability. GPs were similar in the way they took into account 
patient characteristics in the medical and psychological domains in their vulnerability 
assessment, but differed in the way that they weighed the functional status. These find-
ings might be attributed to differences in the education of GPs and the corresponding 
focus on diseases. More uniformity might be achieved when GPs receive additional 
training in the use of a functional model as concept of care.
In conclusion, these two studies support the possibility to select older people at risk 
for deterioration in functioning, as well as older people who are vulnerable according 
to assessment by GPs. However, more studies are needed to compare the outcomes of 
the vulnerability assessment by GPs with those of existing tools that measure vulner-
ability. These analyses might reveal the additional value of screening tools compared 
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to the assessment by GPs (which is simple, not costly and apparently reliable). When 
stratification on vulnerability becomes feasible this will allow to select older individuals 
that, according to GPs (Chapter 2), may benefit from preventive care to maintain their 
independence and wellbeing. 
b. Which preventive strategies are appropriate to contribute to the maintenance of 
independence and wellbeing?
The previous section discussed the possibility to select vulnerable older persons and 
this section examines the usefulness of stratification on vulnerability. The next step is to 
explore whether preventive activities are available for the group of people who require 
maintenance of independence and wellbeing. According to the GPs in the focus group 
discussions (Chapter 2), preventive care for vulnerable people requires an individualized 
approach to prevent functional decline. However, the RAND study investigated whether 
a collective approach could be appropriate to maintain independence and wellbeing 
(Chapter 5). The appropriateness of screening older people to prevent functional decline 
was studied and the outcomes were stratified for levels of vitality status, i.e. the overall 
general population, and a population divided into vital and vulnerable older persons. 
The appropriateness was assessed by an expert panel using the RAND/UCLA appropri-
ateness method. In order to conclude that screening to prevent functional decline is 
appropriate, the screening must at least (in general) approximately meet the criteria 
described by Wilson and Jungner.30 When evidence on fulfilling the criteria of Wilson and 
Jungner was lacking or inconclusive, the experts’ opinions regarding a potential benefit 
to prevent functional decline were taken into account. 
Despite increasing interest in screening of community-dwelling older people and the 
recommendations in guidelines, the expert panel considered screening to maintain 
independence and wellbeing to be appropriate for only a few conditions. Screening 
for insufficient physical activity in order to prevent functional decline was considered 
appropriate for all older persons, without a distinction being made between the level of 
vitality or age. Screening for cardiovascular risk factors and smoking status is considered 
useful for the general older population aged 60-74 years. In the higher age groups, 
however, screening for cardiovascular risk factors and smoking faces lack of evidence, 
because the traditional risk factors no longer accurately predict the cardiovascular risk.31 
There was insufficient evidence to support screening for the other investigated condi-
tions. Interventions that merely stimulate wellbeing (e.g. interventions dealing with 
loneliness) were not considered to be supported by strong evidence. However, based on 
experience, the expert panel expected at least some benefit from these interventions for 
the vulnerable population. For 11 of the 29 investigated conditions, the expert panel was 
uncertain about the appropriateness of screening vulnerable older persons, whereas 
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they considered screening of older people with good vitality for the same condition to 
be inappropriate. Since the majority of vulnerable older persons already receive medical 
care for their chronic disease(s), the expert panel expected more benefit to be derived 
from improving regular medical care than from a separate screening program.
In conclusion, to maintain independence and wellbeing, it is recommended to distin-
guish between vital and vulnerable older people, because most benefit is expected in 
the vulnerable population. However, screening for disorders/ailments might not be the 
appropriate preventive strategy to contribute to the maintenance of independence and 
wellbeing: there is little evidence for such a collective approach and a separate screening 
program might not be the appropriate strategy for vulnerable older persons. Preventive 
care for vulnerable older people probably needs a more individualized approach within 
the structure of regular care. 
3. Prevention of disease, focusing on cardiovascular disease
a. Is it possible to identify subgroups by screening older people to prevent disease?
The focus group study (Chapter 2) revealed that, apart from the national cancer screen-
ing (breast/colon cancer) and vaccination programs, cardiovascular risk management is 
considered the main topic in disease prevention. Chapter 5 shows that cardiovascular 
risk management based on risk stratification appeared to be appropriate in the general 
and vital older population aged 60-74 years to maintain independence and wellbeing, 
although there was uncertainty regarding the vulnerable population. In the general and 
vital older population cardiovascular risk management is considered to be appropri-
ate because it increases life expectancy in these groups and prevents a cardiovascular 
disease-related decrease in functional status. In vulnerable older people, however, 
healthcare professionals did not reach agreement: some rated cardiovascular screening 
as appropriate and others as inappropriate. However, if cardiovascular risk management 
is not applied in this group, not only will the number of cardiovascular deaths increase 
but so will the number of non-fatal cardiovascular diseases, with a further decrease in 
functional status and wellbeing in this population. Therefore, selecting subgroups of 
older people based on risk stratification for cardiovascular disease and death will (po-
tentially) be appropriate for both vital and vulnerable persons because cardiovascular 
risk management prevents death and contributes to the maintenance of independence 
and wellbeing. However, the traditional cardiovascular risk management based on clas-
sic risk factors (like the Framingham Risk Score) is appropriate for people aged ≤75 years 
but is not applicable for those older than 75 years.31 
The Leiden 85-plus Study (Chapter 6) investigated the possibility to select subgroups 
of older people at high risk for cardiovascular morbidity and mortality. In very old 
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community-dwelling people, differences in prognosis between those with various levels 
of prevalent cardiovascular disease were compared with those with no manifest cardio-
vascular disease. The prognosis was studied not only regarding incident cardiovascular 
morbidity and mortality, but also with respect to functional status. Participants with a 
history of major cardiovascular disease had a markedly increased risk of recurrent myo-
cardial infarction, stroke and functional decline, as well as cardiovascular and all-cause 
mortality. Patients with a history of minor cardiovascular disease had a relatively better 
prognosis. Therefore, the extent of the cardiovascular disease history is an easy screen-
ing tool for clinicians to identify patients at high risk for new cardiovascular events, 
functional decline and cardiovascular mortality, as well as all-cause mortality. These 
results encourage both physicians and very old patients with a history of major car-
diovascular disease to maximize their cardiovascular preventive efforts. However, when 
adverse effects/harmful interactions arise in very old patients with minor cardiovascular 
disease, the balance between benefit and harm might change and strict continuation 
of preventive medication might be reconsidered. In the future other cardiovascular risk 
markers might be identified with better high-risk selection mechanisms; however, this 
study shows that even in very old age, risk stratification for cardiovascular morbidity/
mortality is possible in the general older population.
b. Is a high-risk approach an appropriate preventive strategy to contribute to prevention of 
cardiovascular disease in older persons?
The next question to be addressed is whether a high-risk approach not only selects 
people with the highest risk of events, but also those who will derive the most ben-
efit from preventive cardiovascular treatment. Earlier studies showed that even in the 
general older populations, preventive cardiovascular treatment is still effective.32;33 To 
investigate whether preventive cardiovascular intervention is more effective in sub-
groups of older people at highest risk, the effect of preventive pravastatin treatment was 
investigated in three groups at risk for cardiovascular disease stratified on their plasma 
levels of homocysteine. Earlier, De Ruijter et al. showed that in older persons stratifica-
tion based on homocysteine presents a possibility to select those at high cardiovascular 
risk.31 To investigate the effect of preventive treatment in these subgroups, a post-hoc 
subgroup analysis was performed in PROSPER33 (a large double-blinded randomized 
placebo-controlled trial) to assess the effect of pravastatin on risk for coronary heart 
disease and mortality in older persons, stratified for plasma levels of homocysteine. 
Since homocysteine was shown not to be causally related to cardiovascular disease, it 
was unknown which preventive treatment could be offered to those with high homo-
cysteine to reduce their cardiovascular risk. In that study, the non-causal relationship 
between homocysteine and effect of pravastatin was investigated. Although it is cus-
tomary, a causal relation between the predictor and the predicted status is not required. 
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This study revealed that homocysteine may be a promising new coronary heart disease 
risk predictor in older people, since high plasma homocysteine not only selected older 
persons at high-risk for (non)fatal coronary heart disease and all-cause mortality, but 
also identified those with the highest absolute risk reduction by pravastatin and the 
lowest number needed to treat to prevent non(fatal) coronary heart disease. When the 
high-risk population which benefits most from cardiovascular-preventive intervention 
can be selected, this approach might be appropriate for the vital and vulnerable part 
of the older population. Since preventive cardiovascular treatment contributes to life 
expectancy and prevention of functional decline, it contributes to both of the aims 
described in this thesis: prevention of disease, and maintenance of independence and 
wellbeing. This research shows that, to prevent diseases, it is possible to select high-risk 
groups with the most benefit from preventive treatment in the general older popula-
tion; however, more research is needed to develop the optimal screening and treatment 
strategies.
Conclusion 
There is scientific support for the idea that the aim of prevention in older people is not 
only to prevent disease and injury, but also to maintain independence and wellbeing. 
Different strategies and subgroups can be identified for these aims (Figure 1). The aim 
to maintain independence and wellbeing seems to be appropriate for the vulnerable 
population. Although there is no gold standard to stratify for vulnerability in the general 
older population, GPs seem to share the same concept of vulnerability for somatic and 
psychological patient characteristics. Moreover, the variability between GPs will prob-
ably decrease further after additional training in the functional model. Perhaps there 
will not be one ‘best’ overall selection strategy for vulnerability, but perhaps selection 
will depend on the intended interventions. Within the vulnerable older population 
there is no evidence (except for physical activity) that a collective screening approach, 
with a standardized intervention program, will be the appropriate way to contribute to 
the maintenance of independence and wellbeing. This implies that the effort spent in 
preventive health centers for seniors will probably not be effective. Chapter 1 described 
that preventive health centers for seniors can be placed in the lower left quadrant of 
Figure 1, because they use a collective approach to maintain independence and wellbe-
ing.7;34 Since the collective approach seems to be an inappropriate strategy to contribute 
to this aim, it is doubtful whether these health centers fulfill the purpose for which they 
were established. Moreover, it is questionable whether early detection and prevention 
of specific disorders like comorbidity, the responsibility of local authorities according 
to the Dutch Public Health Act, can be organized collectively with a standardized, 
programmatic approach. The limited budgets available for preventive care and research 
can probably be better spent on more promising activities, i.e. those in the upper left 
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and lower right quadrants. Since the majority of vulnerable older people already receive 
medical care for their chronic disease(s), more benefit can be expected from improving 
the individual regular care (in the lower right quadrant) than from a separate screening 
program. The ISCOPE study (a cluster-randomized controlled trial investigating the ef-
fect of pro-active care to patients with complex problems aged ≥75 years) explored this 
individualized approach among vulnerable older people. Moreover, the ‘gut feeling’ of 
GPs in their selection of older people for interventions to maintain independence and 
wellbeing needs further elucidation. 
The traditional aim to prevent diseases can still be applied to the general older popula-
tion, including both vital and vulnerable persons. According to GPs, the main topic in 
the prevention of diseases in the general older population is (apart from the national 
programs) cardiovascular risk management. A collective approach, consisting of high-
risk stratification and treatment, appeared to be possible even at high age. Research on 
this type of collective approach needs to focus on prevention of diseases, not on detec-
tion of disorders which influence independence and wellbeing, because screening does 
not appear to be the appropriate way to contribute to independence and wellbeing. 
Future studies should focus on screening to prevent diseases, such as the development 
of high-risk stratifications in the general older population, especially for cardiovascular 
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Figure 1. Aims and approaches in preventive strategies.
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Finally, the work in this thesis has shown the possibility to develop subgroup specific 
preventive strategies for older people, stratified according to the two defined aims in 
prevention. To do justice to the considerable diversity in health status and vitality of 
older persons, a challenge for future research on the prevention of disease is to incorpo-
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Chapter 1 provides a general introduction and the aims of the work presented in this 
thesis. The chapter outlines the need for risk stratification in older people, and describes 
the increase in the aged population as well as the focus on healthy aging in interna-
tional health policy. According to the Health Council of The Netherlands, prevention 
(i.e. preventive care) in older people can be applied to contribute to the maintenance 
of independence and wellbeing by preventing and/or postponing disability and social 
isolation. However, because prevention traditionally refers to measures taken to pre-
vent disease, injury and death, it is questionable whether prevention can in fact aim 
at maintenance of independence and wellbeing. Therefore, it is important to explore 
the possibility of developing strategies in preventive care for older people in order to 
prevent disease and/or to maintain their independence. 
To develop aim-specific preventive care for older people, we not only need instruments 
to define/select subgroups of older people at risk for disease and/or for loss of indepen-
dence, but we also require adequate collective or individualized strategies to prevent 
disease and/or to maintain independence. Therefore, the general aim of this thesis is 
to study the various strategies (that vary in aim and approach) in prevention for older 
people to facilitate the development of subgroup-specific, evidence-based guidelines 
for preventive care for older persons. 
To explore the aims and approaches in preventive care, Chapter 2 starts with an investi-
gation of the views of general practitioners (GPs) on preventive care for older people. Six 
focus group discussions were held with 37 GPs and were analyzed using the framework 
analysis method. The main finding was that GPs’ perspectives on preventive care are 
determined by their perception of the level of vitality of their older patients. Preventive 
care for older people with high levels of vitality may consist of a standardized disease-
oriented approach, whereas those who are vulnerable will probably need an individual-
ized approach to prevent functional decline. Based on these perspectives, a conceptual 
model for preventive care was developed which describes the different perspectives of 
GPs toward vital and vulnerable older people, focusing on five main dimensions: aim of 
prevention (disease vs. functional decline), concept of care (disease model vs. functional 
model), initiator (older persons themselves vs. the GP), target groups (people with re-
quest vs. specified risk groups) and content of preventive care (mainly cardiovascular 
risk management vs. functional decline). 
In the aim to prevent functional decline and promote wellbeing, the possibility to 
identify subgroups of older people needing different types of care is investigated in the 
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following two chapters. Chapter 3 describes the predictive value of multimorbidity for 
the development of disability in the general population of very old people and the role 
of cognitive impairment in this association. This investigation was part of the Leiden 
85-plus Study, an observational prospective cohort study in the general population with 
5 years of follow-up. In a total of 594 participants (aged 85+ years), without applying 
exclusion criteria, disability in activities of daily living (ADL) was measured annually for 
5 years with the Groningen Activity Restriction Scale. At baseline, participants with mul-
timorbidity had higher ADL disability scores compared with those without (median 11 
vs. 9 ADL points, respectively). Stratified into four groups of cognitive functioning (mea-
sured with the MMSE), ADL disability increased over time in all groups, even in those 
participants without multimorbidity. Multimorbidity predicted accelerated increase in 
ADL disability in participants with optimal (higher) MMSE scores, but not in participants 
with lower MMSE scores. Therefore, in very old people the predictive value of multi-
morbidity for the increase in ADL disability varies with the level of cognitive function; 
multimorbidity predicts an accelerated increase in ADL disability in very old people with 
good cognitive function, but not in very old people with cognitive impairment.
GPs seemed to share an implicit concept of vulnerability (Chapter 2). When the vulner-
ability concepts of GPs appear to be identical, assessment by GPs can be a promising 
instrument to select older people for specific types of geriatric care. Therefore, Chapter 
4 explores the variation in vulnerability concepts between GPs. The analysis was em-
bedded in the Integrated Systematic Care for Older People (ISCOPE) study, a cluster-
randomized controlled trial investigating the effect of pro-active care provided to 
patients (aged ≥ 75 years) with complex problems. A total of 77 GPs categorized their 
registered patients (aged ≥ 75 years; n=11,392) into non-vulnerable, possibly vulnerable 
and vulnerable patients. The personal and practice characteristics of these GPs were col-
lected as well as the characteristics of a sample of 2,828 patients, i.e. socio-demographic 
characteristics, and characteristics in the functional, somatic, psychological and social 
domains. The median percentage of vulnerable patients in this age group per GP was 
32% (range 2.4-81%). The study showed that GPs share a medical concept of vulner-
ability because they take somatic and psychological characteristics into account in the 
vulnerability assessment, but differ in the way that they weigh the functional status. 
After investigation of the possibility to select vulnerable older people (Chapter 4), the 
appropriateness of preventive strategies to contribute to the maintenance of indepen-
dence and wellbeing is studied in Chapter 5. A RAND/UCLA appropriateness method 
was applied to identify appropriate screening conditions to prevent functional decline 
in older people, stratified for age and vulnerability. A multidisciplinary panel of 11 ex-
perts assessed the appropriateness of screening for 29 conditions mentioned in guide-
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lines from four countries, stratified for age (60-74, 75-84 and 85-plus years) and health 
status (general, vital, and vulnerable). The experts received a literature overview for each 
condition, including the guidelines and up-to-date literature. After an individual rating 
round, the expert panel discussed their disagreements and then performed a second 
individual rating. The expert panel rated screening to be appropriate in 3 of the 29 con-
ditions, indicating that screening was expected to prevent functional decline for these 
conditions. Screening for insufficient physical activity was considered appropriate for 
all three age and health groups. Screening for cardiovascular risk factors and smoking 
was considered appropriate for the general and the vital population aged 60-74 years. 
When the experts considered the conditions to be inappropriate, this was mainly due to 
the lack of an adequate screening tool or lack of evidence on effective interventions for 
positively screened persons. Based on their experience, the expert panel expected some 
benefit from developing valid applicable tests and effective interventions, especially for 
the group of vulnerable older people.
To investigate strategies for prevention of disease in the older population, our studies 
then focused on cardiovascular disease. Therefore, in Chapter 6 we investigated differ-
ences in prognosis between very old people with various levels of prevalent cardiovas-
cular disease, compared to those without manifest cardiovascular disease. The rationale 
is that, if this classification on the degree of cardiovascular history proves to reveal differ-
ences in risk, it will be a simple instrument for GPs to select those persons most in need 
of maximization of cardiovascular preventive efforts. Again, this study was performed 
within the Leiden 85-plus Study and was limited to 570 participants with available 
cardiovascular history. The participants were divided into three groups: no history of 
cardiovascular disease (CVD), ‘minor’ CVD (angina pectoris, transient ischemic attack, 
intermittent claudication and/or heart failure), and ‘major’ CVD (myocardial infarction, 
stroke and/or arterial surgery). Investigation of the prognosis took into account not 
only incident cardiovascular morbidity/mortality, but also functional status. At baseline, 
270 (47%) participants had no history of CVD, 128 (22%) minor CVD, and 172 (30%) had 
major CVD. A history of major CVD almost doubled the risk of a recurrent cardiovascular 
event or cardiovascular mortality compared to a history of minor CVD; also, this minor 
CVD group had a 1.6 fold higher risk compared to the no CVD history group. Both minor 
and major CVD were associated with an accelerated decline in cognitive function and 
accelerated increase of disability score, being most pronounced in participants with 
major CVD. These results emphasize the need for physicians and very old patients with a 
history of major CVD to maximize their cardiovascular preventive efforts. However, in the 
case of adverse effects or harmful interactions of medication in a very old patient with 
minor cardiovascular disease, the balance between benefit and harm might change and 
strict continuation of preventive medication might need to be reconsidered. 
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Chapter 7 explores ways to optimize the selection of subgroups that will benefit most 
from preventive cardiovascular medication in old age. This study examines the effect 
of preventive pravastatin treatment in older people stratified into three groups at risk 
for cardiovascular disease based on their plasma levels of homocysteine. A post-hoc 
subanalysis was performed in PROSPER (a large double-blinded randomized placebo-
controlled trial) to assess the effect of pravastatin on the risk for coronary heart disease 
and mortality in older persons, stratified for plasma levels of homocysteine. In the pla-
cebo group, participants with high homocysteine (n=588) had a 1.8 higher risk of (non)
fatal coronary heart disease compared to those with low homocysteine (n=597). Also, 
the number needed to treat (NNT) with pravastatin to prevent one (non)fatal coronary 
heart disease was 15 persons for 3.2 years (the average follow-up period) in the case 
of high homocysteine, whereas in the low homocysteine group the NNT to prevent an 
event was 65 persons for the same period. This study suggests that homocysteine may 
be a promising risk predictor in older people, since high plasma homocysteine not only 
selects older persons at high risk for (non)fatal coronary heart disease and all-cause 
mortality, but also identifies those with the highest absolute risk reduction by pravas-
tatin and lowest NNT to prevent (non)fatal coronary heart disease. 
Finally, Chapter 8 presents a general discussion on the main findings of the work in this 
thesis. The chapter addresses the clinical implications of our results and makes some 
recommendations for further research. The aim of prevention to maintain independence 
and wellbeing seems to be appropriate for the vulnerable population. Although a ‘gold 
standard’ to stratify for vulnerability in the general older population is lacking, GPs share 
the same concept of vulnerability for somatic and psychological patient characteristics. 
However, within the vulnerable older population, there is no evidence (except for physical 
activity) that a collective screening approach, with a standardized intervention program, 
will be the most appropriate way to contribute to the maintenance of independence 
and wellbeing. Moreover, since the majority of vulnerable older people already receive 
medical care for their chronic disease(s), more benefit can be expected from improving 
the individual regular care than from a separate collective screening program. The tradi-
tional aim to prevent disease can be applied to the general older population, including 
both vital and vulnerable persons. According to GPs, cardiovascular risk management is 
the main topic in the prevention of diseases in the general older population, apart from 
the national programs on cancer screening and vaccination. A collective approach in pre-
ventive care, consisting of high-risk stratification and treatment, appeared to be possible 
for cardiovascular risk management even at high age. Because of the great diversity in the 
health status and vitality of older people, it will be challenging to incorporate vulnerability 







Volgens de Gezondheidsraad kan preventie bij ouderen bijdragen aan zelfredzaamheid 
en welzijn, door het voorkomen of uitstellen van invaliditeit en sociaal isolement. Pre-
ventie verwijst echter van oudsher naar maatregelen die worden genomen om ziekte, 
ongevallen en overlijden te voorkomen. Het is de vraag of preventie ook daadwerkelijk 
kan bijdragen aan zelfredzaamheid en welzijn. Daarom is het van belang te onderzoeken 
of preventieve strategieën voor ouderen kunnen worden ontwikkeld ter voorkoming 
van ziekten en ter behoud van zelfredzaamheid.
Om effectieve preventieve zorg voor ouderen te ontwikkelen, is het noodzakelijk dat 
subgroepen van ouderen geselecteerd kunnen worden die een verhoogd risico op ziekte 
of op verlies van zelfredzaamheid hebben. Bovendien moeten er dan collectieve of indi-
viduele strategieën beschikbaar zijn om ziekte te voorkomen of om zelfredzaamheid te 
behouden. Daarom is de doelstelling van dit proefschrift om strategieën in preventieve 
zorg voor ouderen te onderzoeken die variëren in doel en aanpak, ter bevordering van 
de ontwikkeling van evidence based richtlijnen voor preventieve zorg voor subgroepen 
van ouderen.
Hoofdstuk 1 bevat de algemene inleiding en het doel van dit proefschrift. Dit hoofdstuk 
begint met een beschrijving van de behoefte aan risicostratificatie bij oudere mensen, 
omdat de groep ouderen zo divers is wat betreft ziekten, functioneren en levensver-
wachting. Vervolgens wordt de groei van de oudere bevolkingsgroep beschreven en 
wordt aandacht besteed aan de huidige preventieve zorg voor ouderen in Nederland.
Hoofdstuk 2 beschrijft een onderzoek naar de opvattingen van huisartsen over pre-
ventieve zorg voor ouderen. Zes focusgroepbijeenkomsten hebben plaatsgevonden 
met 37 huisartsen. De discussies in deze focusgroepen zijn geanalyseerd met behulp 
van de ‘framework analysis method’. De belangrijkste bevinding in dit onderzoek is dat 
de opvattingen van huisartsen over preventieve zorg vooral werden bepaald door hun 
perceptie van de mate van vitaliteit van hun oudere patiënten. Volgens de huisartsen 
kon preventieve zorg voor vitale ouderen bestaan  uit een gestandaardiseerde ziekte-
specifieke aanpak ter voorkoming van ziekten. Ouderen die kwetsbaar zijn, hebben een 
geïndividualiseerde aanpak nodig om functionele achteruitgang te voorkomen. Op 
basis van deze perspectieven is een conceptueel model voor preventieve zorg ontwik-
keld dat de verschillende opvattingen van huisartsen weergeeft over preventieve zorg 
voor vitale en kwetsbare ouderen. Dit is geordend in vijf dimensies: doel van preventie 
(voorkomen van ziekte versus functionele achteruitgang), zorgconcept (ziektemodel 
versus functioneel model), initiatiefnemer (ouderen zelf versus huisarts), doelgroepen 
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(mensen met een verzoek versus gespecificeerde risicogroepen) en de inhoud van 
preventieve zorg (vooral cardiovasculair risicomanagement versus voorkomen van 
functionele achteruitgang).
Voor het gericht aanbieden van preventie om functionele achteruitgang te voorkomen 
en welzijn te bevorderen is het noodzakelijk om subgroepen van ouderen te kunnen 
selecteren, voor wie een dergelijk preventief aanbod zinvol is. In de volgende twee 
hoofdstukken wordt onderzocht of het mogelijk is subgroepen van ouderen hiervoor 
te selecteren. 
Een mogelijke subgroep van ouderen die achteruitgaan en daarom gericht preventieve 
zorg behoeven, zijn ouderen met multimorbiditeit. Hoofdstuk 3 beschrijft daarom 
de voorspellende waarde van multimorbiditeit voor de ontwikkeling van functionele 
beperkingen in de algemene bevolking van oudste ouderen en de rol van cognitieve 
stoornissen hierin. Deze studie was onderdeel van de Leiden 85-plus Studie, een obser-
vationele prospectieve cohort studie in de algemene bevolking met 5 jaar follow-up. In 
deze studie golden geen exclusiecriteria. Bij alle 594 85-jarige deelnemers werden met 
de Groningen Activity Restriction Scale beperkingen in activiteiten van het dagelijks 
leven (ADL) jaarlijks gemeten gedurende 5 jaar. Op baseline hadden deelnemers met 
multimorbiditeit hogere ADL scores dan deelnemers zonder multimorbiditeit (mediaan 
11 versus 9 ADL punten). De deelnemers werden vervolgens op basis van cognitief 
functioneren, gemeten met de Mini-Mental State Examination (MMSE), gestratificeerd 
in vier groepen. In alle groepen namen de beperkingen in ADL in de loop der tijd toe, 
zowel bij deelnemers met als bij deelnemers zonder multimorbiditeit. Multimorbiditeit 
voorspelde een versnelde stijging van ADL beperkingen bij deelnemers met goede 
MMSE scores (MMSE ≥28 punten), maar niet bij deelnemers met lagere MMSE scores. 
De voorspellende waarde van multimorbiditeit voor de toename in ADL beperkingen 
is derhalve afhankelijk van de cognitieve functie van oudste ouderen: multimorbiditeit 
voorspelt versnelde toename van ADL beperkingen bij oudste ouderen met goede 
cognitieve functie, maar niet bij oudste ouderen met cognitieve stoornissen.
In hoofdstuk 2 leken huisartsen impliciet hetzelfde concept van kwetsbaarheid te 
hanteren. Als het waar is dat huisartsen identieke kwetsbaarheidconcepten gebruiken, 
kan het huisartsenoordeel over kwetsbaarheid een veelbelovend instrument zijn om 
ouderen te selecteren die meer complexe zorg behoeven. Daarom is in hoofdstuk 4 de 
variatie in kwetsbaarheidbeoordelingen tussen de huisartsen onderzocht. De analyse 
werd ingebed in de Integrated Systematic Care for Older People (ISCOPE) study, een 
cluster-gerandomiseerde gecontroleerde trial naar het effect van pro-actieve zorgplan-
ning bij patiënten met complexe problemen van 75 jaar en ouder. Zevenenzeventig 
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huisartsen hebben hun ingeschreven 75-plus patiënten (n=11.392) onderverdeeld in 
niet-kwetsbare, mogelijk kwetsbare en kwetsbare patiënten. Van deze huisartsen werden 
zowel persoonskenmerken als praktijkkenmerken verzameld. Bovendien waren van een 
steekproef van 2828 patiënten de patiëntkenmerken verzameld: socio-demografische 
kenmerken en kenmerken in de functionele, somatische, psychologische en sociale 
domeinen. Het mediane percentage kwetsbare patiënten per huisarts was 32% en vari-
eerde van 2,4 tot 81%. De studie toonde aan dat huisartsen eenzelfde medische invul-
ling gaven aan het begrip kwetsbaarheid, omdat zij de somatische en psychologische 
kenmerken uniform betrokken in het kwetsbaarheidoordeel. De huisartsen verschilden 
echter in de manier waarop ze de functionele status en eenzaamheid van patiënten in 
het kwetsbaarheidoordeel lieten meewegen.
Na onderzoek van de mogelijkheden om kwetsbare ouderen te selecteren (hoofdstuk 
4), wordt in hoofdstuk 5 onderzocht welke screening evidence-based bijdraagt aan 
het bevorderen van zelfredzaamheid van ouderen. Voor dit onderzoek is gebruik ge-
maakt van de ‘RAND/UCLA appropriateness method’. Dit is een methode waarmee een 
multidisciplinair panel op basis van literatuur en expert-opinion evidence kan wegen. 
Elf experts hebben op basis van literatuur en screeningsrichtlijnen uit vier landen de 
evidence voor screening voor 29 onderwerpen gewogen. Voor elk onderwerp werd 
voor drie verschillende leeftijdsgroepen (60-74 jaar, 75-84 jaar, 85-plus) en drie gezond-
heidsniveaus (algemeen, vitaal, kwetsbaar) het nut van screening gescoord, eerst in een 
individuele scoreronde, gevolgd door een paneldiscussie en een tweede individuele 
ronde. Het panel oordeelde dat voor drie van de 29 onderwerpen screening nuttig was: 
screening op onvoldoende fysieke activiteit was zinvol voor alle leeftijdsgroepen en 
alle gezondheidsniveaus. Screening op cardiovasculaire risicofactoren en roken was 
zinvol voor ouderen in de algemene populatie en de vitale ouderen van 60-74 jaar. Het 
ontbreken van een adequaat screeningsinstrument en het ontbreken van evidence over 
de effectiviteit van interventies waren de meest voorkomende redenen om screening 
als ‘niet nuttig’ te kwalificeren. Ontwikkeling van valide screeningsinstrumenten en/of 
effectieve interventies kan in de toekomst bijdragen aan het bevorderen van zelfred-
zaamheid, met name van kwetsbare ouderen.
De volgende hoofdstukken betreffen strategieën voor de preventie van ziekten bij 
ouderen en richten zich specifiek op hart- en vaatziekten. Het doel van hoofdstuk 6 
is om de verschillen in prognose tussen zeer oude mensen met milde en ernstige 
cardiovasculaire voorgeschiedenis te onderzoeken en deze groepen te vergelijken met 
degenen zonder manifeste hart- en vaatziekten in de voorgeschiedenis. Immers, als de 
ernst van de cardiovasculaire geschiedenis het risico op hart- en vaatziekten voorspelt, 
dan is de cardiovasculaire voorgeschiedenis een eenvoudig instrument voor huisartsen 
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om ouderen te selecteren die het meest baat hebben bij specifieke preventieve inter-
venties. Deelnemers van de Leiden 85-plus Studie werden ingedeeld in drie groepen: 
geen cardiovasculaire voorgeschiedenis (47%), milde cardiovasculaire voorgeschiedenis 
(angina pectoris, TIA, claudicatio intermittens en/of hartfalen) (22%) en ernstige cardio-
vasculaire voorgeschiedenis (myocardinfarct, beroerte en/of arteriële chirurgie) (30%). 
In vergelijking met een milde cardiovasculaire voorgeschiedenis werd door een ernstige 
cardiovasculaire voorgeschiedenis het risico op het optreden van een cardiovasculaire 
ziekte of cardiovasculaire mortaliteit vrijwel verdubbeld. Bovendien had de groep met 
een milde cardiovasculaire voorgeschiedenis een 1,6 maal hoger risico op het optreden 
van een cardiovasculaire ziekte dan de groep zonder cardiovasculaire voorgeschiede-
nis. Zowel een milde als een ernstige cardiovasculaire voorgeschiedenis bleken een 
versnelde achteruitgang van cognitief en lichamelijk functioneren te voospellen, alweer 
het meest uitgesproken in de groep met een ernstige cardiovasculaire voorgeschiede-
nis. Deze resultaten tonen het belang om bij ouderen met een ernstige cardiovasculaire 
voorgeschiedenis de cardiovasculaire preventie te maximaliseren. Wanneer echter bij 
oude patiënten met een milde cardiovasculaire voorgeschiedenis bijwerkingen of scha-
delijke interacties van medicatie optreden, kan de balans tussen voor- en nadeel van 
strikte voortzetting van preventieve medicatie anders uitslaan en dient de noodzaak 
van preventieve interventies te worden heroverwogen.
Het volgende hoofdstuk onderzoekt de mogelijkheden om subgroepen te definiëren 
die het meest baat hebben bij preventieve cardiovasculaire medicatie op hoge leeftijd. 
Hoofdstuk 7 beschrijft een studie naar de verschillen in effect van preventieve behan-
deling met pravastatine op cardiovasculair risico bij oudere mensen afhankelijk van hun 
homocysteïne plasmaspiegel. In PROSPER, een grote, dubbelblind gerandomiseerde 
placebo-gecontroleerde studie, werd een post-hoc subanalyse uitgevoerd. In de niet 
behandelde placebogroep hadden deelnemers met een hoog homocysteïne (n=588) 
een 1,8 maal hoger risico op al dan niet fatale coronaire hartziekten dan deelnemers 
met een laag homocysteïne (n=597). Deze studie toonde aan dat 15 mensen met hoog 
homocysteïne behandeld moeten worden (number needed to treat) met pravastatine 
gedurende 3,2 jaar (de gemiddelde follow-up tijd van de studie) om een al dan niet 
fatale coronaire hartziekte te voorkomen. Voor de groep met laag homocysteïne moe-
ten 65 personen gedurende 3,2 jaar behandeld moeten worden om ditzelfde resultaat 
te behalen. Deze studie laat zien dat homocysteïne een veelbelovende nieuwe risico-
voorspeller is voor coronaire hartziekten bij ouderen; met een homocysteïnebepaling 
kunnen ouderen worden geselecteerd die niet alleen een hoog risico op al dan niet 
fatale coronaire hartziekten hebben en algemene sterfte, maar ook degenen bij wie de 
grootste reductie in het absolute risico met pravastatine behaald kan worden. Voor de 
toekomst betekent dit dat dat door het bepalen van het homocysteïne de groep oude-
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ren met de laagste ‘number needed to treat’ kan worden geselecteerd, ter voorkoming 
van al dan niet fatale coronaire hartziekten.
Hoofdstuk 8 bevat de belangrijkste bevindingen, de algemene discussie met aanslui-
tend de klinische implicaties van de bevindingen en aanwijzingen voor verder onder-
zoek. Het bevorderen van zelfredzaamheid lijkt een geschikt doel voor preventie voor 
de groep kwetsbare ouderen. Een gouden standaard om de algemene oudere bevolking 
in te delen naar kwetsbaarheid ontbreekt echter. Huisartsen blijken evenwel eenzelfde 
medisch concept van kwetsbaarheid te hanteren, waarin zij de somatische en psycholo-
gische kenmerken van hun oudere patiënten laten meewegen. Er is echter geen bewijs 
dat het zinvol is om deze groep kwetsbare ouderen te gaan screenen op allerhande 
onderwerpen (met uitzondering van screening op onvoldoende fysieke activiteit). Een 
collectief screeningsaanbod met een gestandaardiseerd interventieprogramma lijkt 
derhalve niet de juiste manier om bij te dragen aan zelfredzaamheid van kwetsbare 
ouderen. Aangezien de meeste kwetsbare ouderen al vanwege hun chronische ziekte(n) 
reguliere zorg ontvangen, lijkt voor deze groep het verbeteren van de individuele zorg 
meer winst te kunnen opleveren dan een afzonderlijk collectief screeningsprogramma. 
Het traditionele doel van preventie om ziekten te voorkomen, blijft een zinvol doel 
voor preventieve programma’s voor ouderen in het algemeen. Huisartsen denken bij 
preventie van ziekten voor de algemene groep ouderen naast de nationale programma’s 
voor kankerscreening en vaccinatie vooral aan cardiovasculair risicomanagement. 
Risicostratificatie in het kader van cardiovasculair risicomanagement is bij ouderen 
mogelijk, zelfs op hoge leeftijd. Bovendien is met behulp van risicostratificatie een 
groep ouderen te selecteren met het hoogste risico op nieuwe coronaire hartziekten 
en is in die groep ook de grootste absolute risicoreductie te bereiken met preventieve 
medicamenteuze behandeling. Gezien het feit dat lang niet alle ouderen met een in-
dicatie voor preventieve cardiovasculaire medicatie deze medicatie ook daadwerkelijk 
slikken, is nader onderzoek noodzakelijk om te bepalen welke ouderen het meeste baat 
hebben bij preventieve medicamenteuze behandeling. Bovendien is het vanwege de 
grote diversiteit in de gezondheidstoestand en vitaliteit van ouderen belangrijk om in 
toekomstig onderzoek naar effecten van preventieve interventies bij ouderen de mate 
van kwetsbaarheid op te nemen in de risicostratificatie.
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Van jarenlang beleid in het ziekenhuis naar onderzoek in de public health en eerstelijns-
geneeskunde was een grote, spannende sprong. Ik kreeg de ruimte en het vertrouwen 
om mij te verdiepen in de vele aspecten van het wetenschappelijk onderzoek. Dat ik 
vanaf het begin de mogelijkheid kreeg om mij ook te blijven ontwikkelen in het gezond-
heidsrecht bij Aart Hendriks, heb ik heel bijzonder gevonden. Het zijn mijn promotoren 
en mijn co-promotor Jeanet Blom geweest die het mogelijk hebben gemaakt dat ik 
onderzoek heb leren doen zonder de rest te verleren.
De afdeling Public Health en Eerstelijnsgeneeskunde heb ik ervaren als een afdeling 
met enthousiaste collega’s, die graag in discussie gaan en daarmee opbouwend hebben 
bijgedragen aan de vorderingen van mijn onderzoek. Dankzij de inzet van de betrok-
ken onderzoeksmedewerkers, heeft de dataverzameling plaats kunnen vinden. Van de 
onderzoekers wil ik in het bijzonder Monique Caljouw bedanken, mijn kamergenoot. 
We hebben heel wat samen nagedacht over ons onderzoek en over onze planningen 
om naast allerlei andere werkzaamheden ook het proefschrift af te ronden. Dat jij mijn 
paranimf wilt zijn, waardeer ik enorm! Ook Wendy den Elzen wil ik bedanken, die mij bij 
mijn eerste analyses geholpen heeft SPSS en statistiek weer onder de knie te krijgen. 
Tot slot wil ik Petra van Peet niet onvermeld laten: naast mijn huidige werk bij de KNMG 
hebben we samen alweer een reeks focusgroepen gedaan, dit onderhoudt mijn lijn met 
de wetenschap! 
In mijn schoonvader wil ik alle ouderen bedanken die meewerken aan wetenschappelijk 
onderzoek. Dankzij die bereidheid hebben wij als onderzoekers een schat aan informatie 
die nodig is om de wetenschappelijke onderzoeksvragen te beantwoorden. Mijn ouders 
wil ik bedanken voor hun interesse en stimulans: van hen heb ik geleerd om je eigen 
interesses te volgen, omdat daarmee altijd nieuwe mogelijkheden ontstaan. Ook zijn zij 
en mijn schoonmoeder altijd bereid om in te springen voor geplande en ongeplande 
oppassen, hartelijk dank daarvoor.
In de familie was er altijd interesse in de vorderingen en de resultaten van mijn on-
derzoek, heel veel dank voor jullie belangstelling! In de vriendenkring wil ik speciaal 
Elsbeth en Jan van Lopik bedanken voor hun interesse en de ontspanning tijdens de 
gezellige afspraken en minivakanties. Elsbeth, ik ben blij dat jij mijn paranimf wilt zijn.
Lieve Marianne, Simone en Bart, van jullie lieve gezelligheid geniet ik elke dag! Jullie zijn 
nieuwsgierig, niet alleen bij jullie eigen bezigheden, maar ook naar het werk van pappa 
en mij. Ik hoop dat jullie die nieuwsgierigheid altijd blijven houden! Tot slot natuurlijk 
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Jan-Kees. Ik ben heel gelukkig met hoe we er voor elkaar zijn en elkaar de ruimte geven. 
Het is leuk dat wij vanuit dezelfde studie zo verschillende wegen zijn gegaan. Omdat we 
vanuit verschillende invalshoeken ‘het vak’ bekijken, geeft praten met jou altijd stof tot 
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